

US 20220273822A1

(19) United States (12) Patent Application Publication (10) Pub. No.: US 2022/0273822 A1

Tang et al.

(10) Pub. No.: US 2022/0273822 A1 (43) Pub. Date: Sep. 1, 2022

(54) ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE

- (71) Applicant: National Institute of Biological Sciences, Beijing, Beijing (CN)
- (72) Inventors: Nan Tang, Beijing (CN); Huijuan Wu, Beijing (CN)
- (73) Assignee: National Institute of Biological Sciences, Beijing, Beijing (CN)
- (21) Appl. No.: 17/614,737
- (22) PCT Filed: May 30, 2019
- (86) PCT No.: PCT/CN2019/089357 § 371 (c)(1),
 - (2) Date: Nov. 29, 2021

Publication Classification

(31)	ш. с.	
	A61K 49/00	(2006.01)
	A61P 11/00	(2006.01)
	A01K 67/027	2006 01 ⁵

(51)

Int Cl

(57) ABSTRACT

The present invention relates to a method for constructing an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), the constructed animal model using the said method, and a method for screening the candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF).

Specification includes a Sequence Listing.





FIG 1













FIG 5











FIG 8

The *Cdc42* sequence before deleting the exon2 of the *Cdc42* gene:

5'TGTTCTATTTTAAAGTACAGGTAATCATGCATGAGAAGTCAAAACCTTTAAAACTGTCAAACAGTGGGCT GCTGTGTGTGGGCATTTGCTGCCAACCATGACAACCTAAGTTCAACTTAAGAGCCCAACAATGGAAAAAGA CCCCTTCAAGTTGTCCTCTGCCATCTACACATACACCAAAGCAGGACACAGGTATGTACAGAATTCATAACT TCGTATAATGTATGCTATACGAAGTTATGTTCGAACGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCGCTA GACTAGTACGCGTGTACACCTTGTAATTGCTGCTCTGAGCAAGTTGCCATTTTTTCTTTTTAGAGGTTTTCAG **TCATAGCAGTAATGCTAGTTCTGGTTTGAGTGGCTGAGCCTGTTGCTAGGGGAAAAAAGTATGGATTTAAAC** ATAAATCAATAAAATAATTGTCTTTAATTTCTTCTTAGGACAAGATCTAATTTGAAATATTAAAAGTGGATACAA AACTGTTTCCGAAATGCAGACAATTAAGTGTGTTGTTGTTGGTGATGGTGCTGTTGGTAAAACATGTCTCCTG ATATCCTACACAAACAAATTCCCATCGGAATATGTACCAACTGTAAGTATAAAGGCTTTTTACTAGCAAAA AGTTATGGTACCGAATTCAGTTTCTGGACCTTGTTGTTTTGTCTTAAGTATCAAAGTAGAACAGTGACCGAT ATATTCCTTTTATTTTTTTTTTTTCTTCCCTGAGACTGGGTTTCTCTGTGTAGCCCTTGCTGTTCTGTAACTCAC GTGGTATATGAAGTATAGTTTGTGAAAGCTGCTTCAGTGTGAGCACACACGCATTATATGCAAGACCAATT GCAGCCCGAAGAATACTCTAAAAAATGACTCACTGCCCAG3' (SEO ID NO:3)

The *Cdc42* sequence after deleting the exon2 of the *Cdc42* gene:

FIG 9

ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE

PRIORITY CLAIM AND CROSS-REFERENCE

[0001] The present application is a National Stage Application, filed under 35 U.S.C. 371, of International Patent Application No. PCT/CN2019/089357, filed on May 30, 2019, which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

[0002] This application contains a Sequence Listing, which is submitted electronically via EFS- Web in ASCII format with a file name H5292-00002-SEQTXT, creation date of Mar. 3, 2022, and a size of 5 kB. This sequence listing submitted is part of the specification and is herein incorporated by reference in its entirety.

[0003] Introduction

[0004] Fibrosis, the thickening and scarring of connective tissue that can result from injury, is characterized by the excessive proliferation of fibroblast cells and the accumulation of extracellular matrix (ECM) components. This disorder, which is commonly observed in organs including lungs, livers, and kidneys, among many others, causes disrupted tissue architecture and leads to major impairments in organ function^{1,2}. Indeed, fibrosis can develop in nearly every organ and is a major cause of end-stage organ failure and death in a large variety of chronic diseases³. A common feature of pulmonary fibrosis is the excessive proliferation of fibroblasts around the air sacs of lungs (alveoli)⁴. Extensive biomedical studies have established that an increased number of fibroblasts, in combination with their excessive ECM deposition in the lung ultimately cause alveolar structure destruction, decreased lung compliance, and disrupted gas exchange function⁵⁻⁷.

[0005] The most common type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). This disorder eventually affects entire lung lobes, but it begins with microscopic fibrotic lesions that occur at the peripheral regions and slowly progress inward, and this fibrosis can ultimately lead to respiratory failure ^{8,9}. IPF is a fatal disease with the median survival time being only 2-4 years from diagnosis¹⁰. The mechanisms and nature of the pathological progression of IPF are not fully understood, although multiple studies have implicated contributions from a specific subset of alveolar epithelial cells-alveolar type II (AT2) cells^{4,11}.

[0006] The alveolar epithelia of lungs are composed of a combination of both alveolar type I (AT1) and type II (AT2) cells. AT2 cells are the alveolar stem cells, and can differentiate into AT1 cells during alveolar homeostasis and post-injury repair^{12,13}. AT1 cells-which ultimately constitute fully 95% of the alveolar surface in adult lungs-are large squamous cells that function as the epithelial component of the thin air-blood barrier¹⁴. In IPF tissues, abnormal hyperplastic AT2 cells are typically located adjacent to fibroblastic foci¹⁵, and the gene mutants that affect the functions of AT2 cells are frequently observed in IPF tissues in the clinic^{16,17}. In addition, recent advances in identifying the molecular profiles of IPF lungs showed that TGF β signaling (a common fibrotic signaling in many fibrotic diseases) is activated in the AT2 cells of IPF lungs¹⁸.

[0007] The pulmonary fibrosis patient has decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. It is estimated that IPF affects 1 of 200 adults over the age of 65 in the United States, with a median survival time of 2-4 years. In China, the estimated incidence of IPF is 3-5/100,000, accounting for about 65% of all interstitial lung diseases. The diagnosis is usually made between 50 and 70 years old, and the ratio of male to female is 1.5 to 2:1. The survival time of the patient is usually only 2-5 years.

[0008] Currently, there is no medicine for curing IPF. Two known drugs, nintedanib and pirfenidone, have similar effects on the rate of decline in forced vital capacity over 1 year. Although both drugs showed a tendency of reducing mortality, these two drugs failed to show significantly increased survival time. One of main reasons is that there is no ideal animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), so as to screen candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF).

[0009] Summary of the Invention

[0010] The present invention relates to a method for constructing an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), the constructed animal model using the said method, and a method for screening the candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF). The present invention provides a constructed disease animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), and the constructed animal model may be used to study pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), to screen candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) in animals and human beings, and to search for drug targets of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) of animals, and human beings.

[0011] In the first place, the present invention provides a method for constructing an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), which comprises the step of increasing the mechanical tension on the alveolar epithelium of the animal.

[0012] Preferably, before the step of increasing the mechanical tension on the alveolar epithelium, the animal undergoes a pneumonectomy (PNX).

[0013] Preferably, the step of increasing the mechanical tension on the alveolar epithelium includes the step of increasing the mechanical tension on alveolar type II (AT2) cells.

[0014] Preferably, the step of increasing the mechanical tension on alveolar type II (AT2) cells involves the step of deactivating Cdc42 in AT2 cells (Cdc42 AT2 null). Deactivating Cdc42 in AT2 cells involves deleting, disrupting, inserting, knocking-out or inactivating Cdc42 genes in AT2 cells.

[0015] Preferably, the present invention provides a method for constructing an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), which comprises the step of knocking-out Cdc42 gene in AT2 cells, preferably, in PNX-treated animal.

[0016] The loss of Cdc42 gene in AT2 cells leads to progressive lung fibrosis in PNX-treated animals. Moreover,

this progressive lung fibrosis phenotype also occurs in non-PNX-treated Cdc42 AT2 null animals in middle age and old age.

[0017] In the lungs of Cdc42 AT2 null animals, fibroblastic foci are developed.

[0018] Preferably, the animal may be mouse, rabbit, rat, canine, pig, horse, cow, sheep, monkey or chimpanzee.

[0019] In the second place, the present invention provides an animal model constructed through increasing the mechanical tension on the alveolar epithelium of the animal. **[0020]** Preferably, the present invention provides an animal model constructed through increasing the mechanical tension on AT2 cells of the animal.

[0021] Preferably, the present invention provides an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), wherein the mechanical tension on the alveolar epithelium of the animal is increased.

[0022] Preferably, the present invention provides an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), wherein Cdc42 gene in AT2 cells is deactivated.

[0023] Preferably, the present invention provides an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), wherein Cdc42 gene in AT2 cells is deleted, disrupted, inserted, knocked-out or inactivated.

[0024] Preferably, the present invention provides an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), wherein Cdc42 gene in AT2 cells is knocked out.

[0025] Preferably, the present invention provides an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), wherein the animal model shows progressive lung fibrosis phenotype after undergoing PNX. Moreover, the present invention provides an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), wherein the animal model without undergoing PNX shows progressive lung fibrosis phenotype in middle age and old age.

[0026] In the disease animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) in the present invention, fibroblastic foci are developed.

[0027] Preferably, the present animal model develops fibrotic changes after the pneumonectomy (PNX) treatment. [0028] Preferably, the present animal model shows genotype of Cdc42 AT2 null.

[0029] Preferably, the present animal model is Cdc42 AT2 null mouse.

[0030] Preferably, the animal may be mouse, rabbit, rat, canine, pig, horse, cow, sheep, monkey or chimpanzee.

[0031] In the third place, the present invention provides an AT2 cell of lung, wherein the mechanical tension on the alveolar epithelium is increased.

[0032] Preferably, the present invention provides an AT2 cell, wherein Cdc42 gene is deactivated. Preferably, the present invention provides an AT2 cell, wherein Cdc42 gene is knocked out. Preferably, the present invention provides a Cdc42 null AT2 cell.

[0033] In the fourth place, the present invention provides a lung, wherein the mechanical tension on the alveolar epithelium is increased.

[0034] Preferably, the present invention provides a lung, wherein Cdc42 gene in the AT2 cells of the lung is deactivated. Preferably, Cdc42 gene in the AT2 cells of the lung is

knocked out. Preferably, the present invention provides a lung having Cdc42 null AT2 cells.

[0035] Preferably, the said lung is obtained by using a Spc-CreER allele to knockout Cdc42 specifically in lung AT2 cells (pulmonary alveolar stem cells).

[0036] In the fifth place, the present invention provides a method for screening candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) of animals and human beings using the said animal model.

[0037] In the sixth place, the present invention provides use of the said animal model or cultured AT2 cells thereof in searching for a drug target aiming at treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) of animals and human beings.

[0038] Preferably, the present invention searched out one kind of drug target, involving a positive feedback loop of TGFI β /SMAD signaling in human or mouse AT2 cells. Preferably, the autocrine TGF β in human or mouse AT2 cells can activate TGF β /SMAD signaling in these AT2 cells. Preferably, mechanical stretching can significantly increase the expression level of autocrine TGF β in both human and mouse AT2 cells. Preferably, the positive feedback loop of TGF β /SMAD signaling in stretched human and mouse AT2 cells further results in the increased expression level of autocrine TGF β .

[0039] In the seventh place, the present invention provides a method for evaluating the therapeutic effects of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) using the said animal model.

[0040] In the eighth place, the present invention provides a method for the prognosis evaluation of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) using the said animal model.

[0041] In the ninth place, the present invention provides use of the said animal model for screening candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) of animals and human beings.

[0042] In the tenth place, the present invention provides a method for detecting the said animal model using a pair of primers designed on the basis of the sequences shown by SEQ ID NO:4.

[0043] Preferably, the primers for detecting the said animal model are shown as followed:

Forward:	(CEO	TD	NO	1 \
CTGCCAACCATGACAACCTAA;	(SEQ	тD	NO:	1)
Reverse:	(680	TD	NO	2)
AGACAAAACAACAAGGTCCAG.	(SEQ	τD	110:	⊿)

[0044] The Cdc42 null AT2 cells are unable to differentiate into ATI cells and thus cannot regenerate new alveoli after lung injuries, the alveolar epithelium of Cdc42 AT2 null mice continues to experience elevated mechanical tension. **[0045]** The invention encompasses all combination of the particular embodiments recited herein.

[0046] Brief Description of the Drawings

[0047] FIG. 1 shows the expression level of CDC42-GTP (the active form of CDC42) increases significantly at post-PNX day 7, which is the time when AT2 cells differentiate into AT1 cells.

[0048] FIG. **2** shows the scheme of generating a mouse line in which Cdc42 gene is specifically deleted in AT2 cells.

[0049] FIG. **3** shows that loss of Cdc42 gene in AT2 cells impairs the differentiation of AT2 cells during post-PNX alveolar regeneration or alveolar homeostasis

[0050] FIG. 4 shows that loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in PNX-treated mice.

[0051] FIG. **5** shows that loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in non- PNX-treated aged mice **[0052]** FIG. **6** shows the development of a-SMA⁺fibroblastic foci in the lungs of PNX- treated Cdc42 AT2 null mice.

[0053] FIG. 7 shows that elevated mechanical tension activates an autocrine TGF β signaling in mouse and human AT2 cells.

[0054] FIG. 8 shows increased TGF β signaling in AT2 cells of PNX-treated Cdc42 AT2 null mice and IPF patients. And decreasing TGF β signaling in AT2 cells of PNX-treated Cdc42 AT2 null mice attenuating the fibrosis development. [0055] FIG. 9 shows the fragments of Cdc42 DNA sequence before and after deleting the exon2 of the Cdc42 gene.

[0056] Description of Particular Embodiments of the Invention

[0057] The descriptions of particular embodiments and examples are provided by way of illustration and not by way of limitation. Those skilled in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

[0058] The idiopathic pulmonary fibrosis (IPF) is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired and nail clubbing. Complications may include pulmonary hypertension, heart failure, pneumonia, or pulmonary embolism.

[0059] The alveolar epithelia of lungs are composed of a combination of both alveolar type I (AT1) and type II (AT2) cells. AT2 cells are the alveolar stem cells, and can differentiate into AT1 cells during alveolar homeostasis and post-injury repair. AT1 cells-which ultimately comprise fully 95% of the alveolar surface in adult lungs-are large squamous cells that function as the epithelial component of the thin air-blood barrier¹⁴. In IPF tissues, abnormal hyperplastic AT2 cells are typically located adjacent to fibroblastic foci's, and the gene mutants that affect the functions of AT2 cells are frequently observed in IPF tissues in the clinic¹⁶⁺¹⁷. The precise pathological mechanisms underlying abnormal AT2 physiology and progressive pulmonary fibrosis remain to be elucidated.

[0060] "Animal model" or "disease animal model" is a living, non-human animal used for research and investigation of human diseases, for the purpose of better understanding the disease process, the pathological mechanisms, and for the purpose of screening effective drugs and searching for ideal drug targets.

[0061] Searching for potential drug target(s) for a disease is the first step in the discovery of a drug, and is also the key point for screening new drugs for a disease.

[0062] In an embodiment of the present invention, based on the findings that the expression level of CDC42-GTP in the post-PNX lungs (having significantly increases mechanical tension) is increased significantly (FIGS. 1A and 1B), and such increased expression of CDC42-GTP can be inhibited by a prosthesis implantation (FIGS. 1A and 1B), the effect of deleting Cdc42 genes in AT2 cells during PNX- induced alveolar regeneration is investigated in the present invention. **P<0.01, Student's t test.

[0063] The Sftpc gene promoter-driven recombinase (Spc-CreER) is used to specifically delete genes in AT2 cells after administration of tamoxifen to the animal. The CreER mouse system is commonly used for inducible gene knock-out studies.

[0064] In an embodiment of the present invention, a mouse line in which Cdc42 gene is specifically deleted in AT2 cells is constructed. The mouse in the present invention is named as Cdc42 AT2 null mice (FIG. **2**). In the lungs of Cdc42 AT2 null mice, few AT2 cells differentiated into AT1 cells, and no new alveoli are formed at post-PNX day 21 (FIG. **3**B).

[0065] In an embodiment of the present invention, some Cdc42 AT2 null mice showed significant weight loss and increased respiration rates after PNX treatment day 21 (FIGS. 4A and 4B). Indeed, fully 50% of PNX-treated Cdc42 AT2 null mice reached the predefined health- status criteria for endpoint euthanization by post-PNX day 60 (FIG. 4B), and about 80% of PNX-treated Cdc42 AT2 null mice reached their endpoints by post-PNX day 180 (FIG. 4B). Cdc42 AT2 null mice revealed severe fibrosis in their lungs at their endpoints (FIG. 4D).

[0066] In an embodiment of the present invention, Cdc42 AT2 null mice after PNX reveal severe fibrosis in the lungs of Cdc42 AT2 null mice at their endpoints (FIG. 4D compared with FIG. 4C). The subpleural regions of some Cdc42 AT2 null lungs exhibit signs of tissue thickening starting from post-PNX day 21 (FIG. 4D). By the end-point, the dense fibrosis has progressed to the center of most Cdc42 AT2 null lungs.

[0067] In an embodiment of the present invention, Collagen I is detected in the dense fibrotic regions in the lungs of Cdc42 AT2 null mice (FIG. 4E), and the proportion of Collagen I expressing area per lobe gradually increases in Cdc42 AT2 null mice after PNX treatment (FIG. 4F). The qPCR analysis also shows that the Collagen I mRNA expression level increases gradually from post-PNX day 21 (FIG. 4G). Moreover, gradually decreased lung compliance is observed in PNX-treated Cdc42 AT2 null mice from post-PNX day 21 as compared to their PNX-treated Control mice (FIG. 4H). Decreased lung compliance is known to occur frequently as lungs become fibrotic¹⁹⁻²⁴.

[0068] In an embodiment of the present invention, Cdc42 AT2 null mice without PNX treatment from 10-months of age to 24-months of age (FIG. **5**A) show that no significant fibrotic changes before the Cdc42 AT2 null mice reach 10-months of age (FIG. **5**C). Fibrotic changes in the lungs of control mice are never observed, even the control mice reached 24- months of age (FIG. **5**B), but, by 12 months, fibrosis have obviously begun to develop in the subpleural regions of Cdc42 AT2 null lungs and to progress toward the center of the lung (FIG. **5**C).

[0069] Fibroblastic foci are considered as a relevant morphologic marker of progressive pulmonary fibrosis and are recognized as sites where fibrotic responses are initiated and/or perpetuated in progressive pulmonary fibrosis. The fibroblastic foci contain proliferating α - SMA⁺fibroblasts.

[0070] In an embodiment of the present invention, it is observed that some α -SMA⁺fibroblasts start to accumulate next to a cluster of AT2 cells in the relative normal alveolar regions of Cdc42 AT2 null lungs (area 1, FIG. 6A). And the dense fibrosis region of the lungs is filled with α -SMA⁺

fibroblasts (area **2**, FIG. **6**A). In addition, the cell proliferation of α -SMA⁺cells increases dramatically in the lungs of Cdc42 AT2 null mice at post-PNX day 21, indicating that the proliferating α -SMA⁺fibroblasts contribute to the development of lung fibrosis (FIG. **6**B).

EXAMPLES

[0071] Methods

[0072] Mice and survival curve record.

[0073] Rosa26-CAG-mTmG (Rosa26-mTmG), Cdc42 *flox/flox* mice²⁵, and Tgfbr2 mice²⁶ have been described previously. All experiments were performed in accordance with the recommendations in the Guide for Care and Use of Laboratory Animals of the National Institute of Biological Sciences. To monitor the survival of mice, both the Control and the Cdc42 AT2 null mice were weighed every week after the PNX treatment. Once the mice reached the pre- defined criteria for end-points, the mice were sacrificed. We define the endpoints according to the pre-defined criteria^{27,28}.

[0074] Generating Spc-CreER;rtTA (Spc-CreER) knockin mice.

[0075] The CreERT2, p2a, and rtTA element were enzyme-linked and inserted into the mouse endogenous SPC gene. The insertion site is the stop codon of the endogenous SPC gene, then a new stop codon was created at the 3' end of rtTA. The CRISPR/Cas9 technology was used to insert the CreERT2-p2a-rtTA fragment into the genome.

[0076] Pneumonectomy (PNX) and prosthesis implantation.

[0077] The male mice of 8 weeks old were injected with tamoxifen (dosage: 75mg/kg) every other day for 4 times. The mice were anesthetized and connected to a ventilator (Kent Scientific, Topo) from 14^{th} day after the final dose of tamoxifen injection. The chest wall was incised at the fourth intercostal ribs and the left lung lobe was removed. For prosthesis implantation, a soft silicone prosthesis with a similar size and shape of the left lung lobe was inserted into the empty left lung cavity.

[0078] Pulmonary function test.

[0079] Lung function parameters were measured using the invasive pulmonary function testing system (DSI Buxco® PFT Controller). Mice were first anesthetized before inserting an endotracheal cannula into their trachea. The dynamic compliance results were obtained from Resistance & Compliance Test. The forced vital capacity results were obtained from the Pressure Volume Test.

[0080] Hematoxylin and Eosin (H&E) staining and immunostaining.

[0081] Lungs were inflated with 4% paraformaldehyde (PFA) and were continually fixed in 4% PFA at 4° C. for 24 hours. Then the lungs were cryoprotected in 30% sucrose and embedded in OCT (Tissue Tek).

[0082] The H&E staining experiment followed the standard H&E protocol. Briefly, slides were washed by water to remove the OCT. The nuclei were stained by hemotoxylin (Abcam, ab150678) for 2 minutes and the cytoplasm was stained by eosin (Sigma, HT110280) for 3 minutes. Slices were sealed with neutral resin after the dehydration and clearing steps.

[0083] The immunofluorescence staining experiments followed the protocol previously described²⁹. In brief, after removing the OCT, the lung slices were blocked with 3%BSA/0.1%TritonX-100/PBS for 1 hour, then slides were incubated with primary antibodies at 4° C. for overnight.

After washing the slides with 0.1%TritonX-100/PBS for 3 times, the slices were incubated with secondary antibodies for 2 hours at room temperature.

[0084] The primary antibodies used in the paper are listed below:

Name	Company and catalog number	Dilution	
Chicken anti-GFP Rabbit anti-Collagen I Mouse anti a-SMA Rabbit anti pSmad2 Mouse anti HT2-280 Hamster anti-Pdpn	Abcam, ab13970-100 Abcam, ab34710 Sigma, C6198 CST, #3101 Terrace Biotech, TB-27AHT2-280 Developmental Studies Hybridoma Bank clope8 1 1	1:500 1:300 1:300 1:500 1:50 1:100	

[0085] The secondary antibodies used in the paper are listed below:

Name	Company and catalog number	Dilution
Alexa Fluor 488 Donkey anti-Chicken	703-545-155, Jackson Immuno Research	1:500
Alexa Fluor 488 Donkey anti-mouse	715-545-150, Jackson Immuno Research	1:500
Alexa Fluor 568 Donkey anti-rabbit	A11057, Invitrogen	1:500
Alexa Fluor 647 Goat anti-hamster	A-21451, Invitrogen	1:500
Biotin Donkey Anti- Rabbit	711-065-152, Jackson Immuno Research	

[0086] For the p-SMAD2 staining experiment, 1X phosphatase inhibitor (Bimake, B15002) was added in 4% PFA during the tissue fixation process. The tyramide signal amplification method was used for pSMAD2 staining.

[0087] The human lung tissues were fixed with 4% PFA for 24 hours at 4° C., cryoprotected in 30% sucrose and embedded in OCT. All experiments were performed with the Institutional Review Board approval at both National Institute of Biological Sciences and China-Japan Friendship Hospital.

[0088] Statistical analysis.

[0089] All data are presented as mean \pm s.e.m. (as indicated in figure legends). The data presented in the figures were collected from multiple independent experiments that were performed on different days using different mice. Unless otherwise mentioned, most of the data presented in figure panels are based on at least three independent experiments. The inferential statistical significance of differences between sample means was evaluated using two-tailed unpaired Student's t-tests.

[0090] Isolating mouse AT2 cells.

[0091] After 4 doses of tamoxifen injection, the lungs of Spc-CreER, Rosa26-mTmG mice were dissociated as previously described^{19,44}. Briefly, anesthetized mice were inflated with neutral protease (Worthington-Biochem, LS02111) and DNase I (Roche, 10104159001). AT2 cells were directly sorted based on the GFP fluorescence using the single-cell-select-mode in BD FACS Aria II and III appliances.

[0092] Isolating human AT2 cells.

[0093] The human lung tissues were cut into small pieces with a scalpel, then digested by neutral protease (Worthington-Biochem, LS02111), DNase I (Roche, 10104159001), collagenase type I (Gibco, 17100-017) and elastase (Wor-

thington, 2294). Then the digested suspension was sorted for CD326⁺, HTII-280⁺CD45⁻, CD31⁻ cells using the singlecell-select- mode in BD FACS Aria II and III appliances. All experiments were performed with the Institutional Review Board approval at both National Institute of Biological Sciences, Beijing and China-Japan Friendship Hospital, Beijing.

[0094] Primary human and mouse AT2 cell culture and cell stretching assay.

[0095] Primary AT2 cells were sorted by FACS and plated on silicone membranes for 24 hours before performing the stretching experiments. The equiaxial strain system and methods were previously described in details³⁰. 24 hours after performing a static stretch with a 25% change in surface area, primary AT2 cells were assayed for anti-p-SMAD2 staining. To culture with a TGF β neutralizing antibody (biolegend, 521703) with stretched human or mouse AT2 cells, 1µg/ml TGF β neutralizing antibody was added in the culture medium.

[0096] Quantitative RT-PCR (qPCR).

[0097] Total RNA was isolated from either whole lung or primary AT2 cells using Zymo Research RNA Mini Prep Kits (R2050). Reverse transcription reactions were performed with a two-step cDNA synthesis Kit (Takara, Cat. # 6210A/B) according to the manufacturer's recommendations. qPCR was done with a CFX96 Touch[™]Real-Time PCR Detection System. The mRNA levels of target genes were normalized to the Gapdh mRNA level.

[0098] Primers used for qPCR are listed below.

	Forward	Reverse
Gapdh	AAGGTCGGTGTGAACGGAT TTGG(SEQ ID NO: 5)	CGTTGAATTTGCCGTGAGT GGAG(SEQ ID NO: 6)
Collal	CCTCAGGGTATTGCTGGAC AAC(SEQ ID NO: 7)	CAGAAGGACCTTGTTTGCC AGG(SEQ ID NO: 8)
Human Tgfb1	TACCTGAACCCGTGTTGCT CTC(SEQ ID NO: 9)	GTTGCTGAGGTATCGCCAG GAA(SEQ ID NO: 10)
Mouse Tgfb1	TGATACGCCTGAGTGGCTG TCT(SEQ ID NO: 11)	CACAAGAGCAGTGAGCGCT GAA(SEQ ID NO: 12)

[0099] 3D alveolar reconstruction.

[0100] For vibratome sections, lungs were gently inflated to full capacity with 2% low-melting agarose. Then lungs were fixed in 4% PFA for overnight at 4° C. Thick vibratome sections were sliced at a thicknesses of 200µm using the vibrating microtome (Leica VTIOOS). Immunostaining experiments were performed as the standard wholemount staining protocol. Z stack images were taken by Leica LSI macro confocal microscope and/or A1-R inverted confocal microscope.

[0101] CDC42-GTP assay.

[0102] The GTP-CDC42 level is determined using the CDC42 activation assay biochem kit (cytoskeleton, #BK127) according to the provided manufacturer's recommendations. Briefly, the whole lung lobes were grinded in liquid nitrogen, then lysed using the cell lysis buffer (applied in the kit). Then the cell lysates were added into the microplate wells applied. After the reaction, the absorbance at 490nm was measured.

[0103] Primer sequences for sequencing the fragment of Cdc42 DNA sequence before and after deleting the exon2 of

the Cdc42: Forward: CTGCCAACCATGACAACCTAA (SEQ ID NO:1) ; Reverse: AGACAAAACAACAACGTCCAG(SEQ ID NO:2).

[0104] Example 1. Generating a mouse line in which Cdc42 gene is specifically deleted in AT2 cells

[0105] 1. In order to construct a progressive lung fibrosis animal model, Cdc42 AT2 null mice are generated by knocking out Cdc42 gene specifically in alveolar type II cells (AT2 cells).

[0106] In order to specifically delete Cdc42 gene in AT2 cells, mice carrying a Spc-CreER knock-in allele are crossed with Cdc42 floxed (Cdc42^{*flox/flox*}) mice (FIG. **2**A). In Cdc42 flox/*flox* mice, the exon 2 of Cdc42 gene, which contains the translation initiation exon of Cdc42 gene, is flanked by two loxp sites. In Spc-CreER; Cdc42 flox/*flox* mice the exon 2 of Cdc42 gene, exon 2 of Cdc42 gene is specifically deleted in AT2 cells by Cre/loxp-mediated recombination after tamox-ifen treatment (FIG. **2**B). Spc-CreER; Cdc42^{*flox/flox*} mice are named as Cdc42 AT2 null mice.

[0107] 2. Lungs of Cdc42 AT2 null mice develop progressive fibrotic changes after PNX treatment.

[0108] Left lung lobe resection (peumonectomy, PNX) on Cdc42 AT2 null mice and control mice were performed. The lungs of Cdc42 AT2 null mice and control mice at different time points after PNX treatment were analyzed (FIG. 4A). We found that some Cdc42 AT2 null mice showed significant weight loss and increased respiration rates after post-PNX day 21. Indeed, fully 50% of PNX-treated Cdc42 AT2 null mice reached the predefined health-status criteria for endpoint euthanization by post-PNX day 60 (FIG. 4B), and more than 70% of PNX-treated Cdc42 AT2 null mice (n=33) reached their endpoints by post-PNX day 180 (FIG. 4B). H&E staining shows lungs of sham-treated and PNX-treated control mice do not shown fibrotic changes (FIG. 4C). H&E staining shows that lungs of PNX-treated Cdc42 AT2 null mice at endpoints have significantly increased fibrotic area than the lungs at post-PNX day 21 (FIG. 4D).

[0109] 3. Developing fibrotic changes at the edge of lungs of Cdc42 AT2 null mice at post- PNX day 21.

[0110] The lungs of Cdc42 AT2 null mice start to show fibrotic changes at post-PNX day 21. The Spc-Cdc42^{*f*/ox/-} lungs have shown dense fibrotic changes at the edge of lungs (FIG. **4**D). H&E staining shows that histological changes of the fibrotic region of Cdc42 AT2 null lungs recapitulates the histological changes of human IPF lungs.

[0111] 4. Characterizing the collagen I deposition in fibrotic lungs, and analyzing lung compliance.

[0112] Lungs collected from Control and Cdc42 AT2 null mice at post-PNX day 21 were stained with an anti-Collagen I antibody (FIG. 4E). Much stronger immunofluorescence signals for Collagen I are detected in the dense fibrotic regions of lungs of Cdc42 AT2 null mice as compared with control lungs. The area of dense Collagen I in lungs of Cdc42 AT2 null mice gradually increases from post-PNX day 21 to post-PNX day 60 (FIG. 4F). qPCR analysis showed that the Collagen I mRNA expression levels increased gradually from post-PNX day 21 to post-PNX day 21 to post-PNX day 60 in lungs of Cdc42 AT2 null mice (FIG. 4G). *P<0.05, ***P<0.001; ****P<0.0001, Student's t test.

[0113] The lung compliance of lungs of Cdc42 AT2 null mice gradually decreases after PNX.

[0114] 5. Developing progressive lung fibrosis in no-PNX-treated Cdc42 AT2 null mice starting from around 12 months of age.

[0115] Control and Cdc42 AT2 null mice were exposed to 4 doses of tamoxifen 14 days starting at age of 2 months. Lungs of Control and Cdc42 AT2 null mice without PNX treatment were collected at 10, 12, 16, or 24 months (FIG. **5**A). The lungs of Control and Cdc42 AT2 null mice without PNX treatment were analyzed and found no significant fibrotic changes before the Cdc42 AT2 null mice reached 10-months of age (FIGS. **5**B and **5**C). By 12 months, fibrosis had obviously begun to develop in the subpleural regions of Cdc42 AT2 null lungs and to progress toward the center of the lung (FIG. **5**C). Thus, the loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in no-PNX-treated Cdc42 AT2 null mice starting from around 12 months of age.

[0116] 6. Characterization of the development of α -SMA⁺ fibroblastic foci in the lungs of Cdc42 AT2 null mice.

[0117] Fibroblastic foci are considered a relevant morphologic marker of progressive pulmonary fibrosis and are recognized as sites where fibrotic responses are initiated and/or perpetuated in progressive pulmonary fibrosis³¹. The fibroblastic foci contain proliferating α - SMA⁺fibroblasts³² . Lungs of Cdc42 AT2 null mice at post-PNX day 21 were stained with antibodies against α -SMA (FIG. 6A). Some α -SMA⁺fibroblasts started to accumulate next to a cluster of AT2 cells in the relative normal alveolar regions of Cdc42 AT2 null lungs (area 1, FIG. 6A). And the dense fibrosis region of the lungs is filled with α -SMA⁺fibroblasts (area 2, FIG. 6A). In addition, the cell proliferation of α -SMA⁺cells increased dramatically in the lungs of Cdc42 AT2 null mice at post-PNX day 21 by immunostaining using antibodies against both α-SMA and proliferation marker, Ki67. These results indicate that the proliferating α - SMA⁺fibroblasts contribute to the development of lung fibrosis (FIG. 6B). **P<0.01, Student's t test.

[0118] Example 2. Sequence characterization of the Cdc42 AT2 null mice

[0119] The Spc-CreER, Cdc42 *flox/-* mice were performed genome purification and PCR amplification. Then the fox and null bands of Cdc42 were purified and sequenced using the primers as below: CTGCC AA CC ATG AC AACCTAA (SEQ ID NO: 1); AGACAAAACAACAACGGTCCAG (SEQ ID NO:2).

[0120] The fragments of Cdc42 DNA sequence before or after deleting the exon2 of the Cdc42 gene are shown in FIG. **9**.

[0121] Examples 1 and 2 demonstrate that Cdc42 AT2 null mice are exactly the disease animals of progressive pulmonary fibrosis, in particular, IPF. The following examples show the features of the Cdc42 AT2 null mice, and the uses of the Cdc42 AT2 null mice.

[0122] Example 3. Cdc42 is essential for the differentiation of AT2 cells during post-PNX alveolar regeneration or under normal alveolar homeostasis conditions.

[0123] We performed PNX on control and Cdc42 AT2 null mice and analyzed the alveolar regeneration and AT2 cell differentiation at post-PNX day 21. As shown in FIG. **3**A, 200µm lung sections of control and Cdc42 AT2 null mice are immunostained with antibodies against GFP, Pdpn, and Prospc. At post-PNX day 21, many newly differentiated AT1 cells and newly formed alveoli are observed in no-prosthesis-implanted control lungs (FIG. **3**B). However, in Cdc42 AT2 null lungs, few AT2 cells have differentiated into AT1 cells, and no new alveoli are formed at post-PNX day 21

(FIG. **3**B). It is observed that the alveoli in peripheral region of the Cdc42 AT2 null lungs are profoundly overstretched (FIG. **3**B).

[0124] Under normal homeostatic conditions, AT2 cells slowly self-renew and differentiate into AT1 cells to establish new alveoli. To examine whether Cdc42 is required for AT2 cell differentiation during homeostasis, we deleted Cdc42 in AT2 cells when the mice were two- months old and analyzed the fate of AT2 cells until the mice were 12-month old. Lungs of Control and Cdc42 null mice without PNX treatment were collected at 12 months (FIG. **3**C). Images show the maximum intensity of a 200µm Z-projection of lung sections that were stained with antibodies against GFP, Pdpn, and Prospc. In the lungs of 12-month Control mice, we observed formation of many new alveoli (FIG. **3**D). However, in the lungs of 12-month Cdc42 null mice (that had not undergone PNX), we observed enlarged alveoli with lacking any new AT1 cell formation (FIG. **3**D).

[0125] Example 4. Loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in PNX- treated mice

[0126] Cdc42 AT2 null and control mice after PNX are observed for a longer period of time (FIG. **4**A). Surprisingly, some Cdc42 AT2 null mice showed significant weight loss and increased respiration rates after post-PNX day 21. Indeed, fully 50% of PNX-treated Cdc42 AT2 null mice reached the predefined health-status criteria for endpoint euthanization by post-PNX day 60 (FIG. **4**B), and about 80% of PNX-treated Cdc42 AT2 null mice reached their endpoints by post-PNX day 180 (FIG. **4**B).

[0127] H&E staining of post-PNX control and Cdc42 AT2 null mice reveals severe fibrosis in the lungs of Cdc42 AT2 null mice at their endpoints (FIG. 4D compared with FIG. 4C). In order to determine the point at which Cdc42 AT2 null mice begin to develop lung fibrosis following PNX, the lungs of Cdc42 AT2 null mice are analyzed at various time points after PNX using H&E staining (FIG. 4D). The subpleural regions of some Cdc42 AT2 null lungs exhibit signs of tissue thickening by post-PNX day 21 (FIG. 4D). By the end-point, the dense fibrosis has progressed to the center of most Cdc42 AT2 null lungs (FIG. 4D). What we have observed in post-PNX and aged Cdc42 AT2 null mice is similar to the characteristic progression of IPF, in which fibrotic lesions first occur at the lung periphery and subsequently progress inward towards the center of lung lobes.

[0128] In addition to detecting strong immunofluorescence signals for Collagen I in these dense fibrotic regions of lungs of Cdc42 AT2 null mice (FIG. 4E), we observe the proportion of Collagen I expressing area per lobe gradually increased after PNX in Cdc42 AT2 null mice (FIG. 4F). Our qPCR analysis also shows that the Collagen I mRNA expression levels increase gradually from post-PNX day 21 (FIG. 4G). Moreover, gradually decreased lung compliance is observed in PNX-treated Cdc42 AT2 null mice from post-PNX day 21 as compared to their PNX-treated Control mice (FIG. 4H), an intriguing finding given that decreased lung compliance is known to occur frequently as lungs become fibrotic¹⁹⁻²⁴.

[0129] Example 5. Loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in non- PNX-treated aged mice

[0130] Since it is found that impaired AT2 differentiation and enlarged alveoli in 12-month old Cdc42 AT2 null mice (FIG. **3**D), then lungs of control and Cdc42 AT2 null mice without PNX treatment are analyzed from 10-months of age to 24-months of age (FIG. **5**A). Fibrotic changes in the lungs of control mice are never observed, even the control mice reached 24- months of age (FIG. **5**B). We found no significant fibrotic changes before the Cdc42 AT2 null mice reached 10-months of age (FIG. **5**C). It is also observed that by 12 months, fibrosis has obviously begun to develop in the subpleural regions of Cdc42 AT2 null lungs and to progress toward the center of the lung after 12 months (FIG. **5**C).

[0131] Collectively, the loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in PNX- treated mice. Moreover, this progressive lung fibrosis phenotype also occurs in no-PNX-treated Cdc42 AT2 null mice starting from around 12 months of age. All these results demonstrate that deletion of Cdc42 in AT2 cells leads to IPF like progressive pulmonary fibrosis in mice, and therefore, a mouse model of IPF like progressive lung fibrosis is established and can be used to study human IPF disease.

[0132] Example 6. The development of α -SMA⁺fibroblastic foci in the lungs of Cdc42 AT2 null mice

[0133] Fibroblastic foci are considered a relevant morphologic marker of progressive pulmonary fibrosis and are recognized as sites where fibrotic responses are initiated and/or perpetuated in progressive pulmonary fibrosis. The fibroblastic foci contain proliferating α - SMA⁺fibroblasts. Lungs of Cdc42 AT2 null mice at post-PNX day 21 are stained with antibodies against α -SMA (FIG. 6A). Some α -SMA⁺fibroblasts started to accumulate next to a cluster of AT2 cells in the relative normal alveolar regions of Cdc42 AT2 null lungs are observed (area 1, FIG. 6A). And the dense fibrosis region of the lungs is filled with α -SMA⁺ fibroblasts (area 2, FIG. 6A). In addition, by immunostaining using antibodies against both α - SMA and proliferation marker, Ki67, we show that the cell proliferation of α -SMA⁺ cells is increased dramatically in the lungs of Cdc42 AT2 null mice at post-PNX day 21. These results indicate that the proliferating a-SMA+fibroblasts contribute to the development of lung fibrosis in the lungs of Cdc42 AT2 null mice (FIG. 6B).

[0134] Example 7. Elevated mechanical tension caused by impaired alveolar regeneration leads to progressive lung fibrosis

[0135] The fact that lung fibrosis in Cdc42 AT2 null mice is greatly accelerated by the PNX treatment (FIG. **4**) suggests a close link between lung fibrosis and mechanical tension-induced alveolar regeneration.

[0136] The loss of alveoli resulting from PNX substantially increases mechanical tension exerted upon the alveolar epithelium. The subsequent efficient regeneration of alveoli that occurs in normal mice eventually reduces the intensity of the mechanical tension to pre-PNX levels; however, as Cdc42 null AT2 cells are unable to differentiate into AT1 cells and thus cannot regenerate new alveoli (FIGS. **3**A and **3**B), the alveolar epithelium of Cdc42 AT2 null mice continue to experience elevated mechanical tension, which results in the progressive development of fibrosis (FIG. **4**). [0137] Example 8. Elevated mechanical tension activates a positive feedback loop of TGF β /SMAD signaling in AT2 cells

[0138] Our results provide compelling evidence that elevated mechanical tension on the alveolar epithelium is critical for the progression of lung fibrosis. Using our previously established equibiaxial strain cell culture system, we cultured human or mouse AT2 cells on silicon membranes under either stretched or non-stretched condition (FIG. 7A). We have demonstrated that the application of

mechanical tension to primary mouse and human AT2 cells can significantly increase the expression level of autocrine TGF β , a fibrotic factor (FIG. 7B). To analyze whether the TGFβproduced by AT2 cells can activate the TGFβ/SMAD signaling in AT2 cells, we cultured human or mouse AT2 cells on silicon membranes under either stretched or nonstretched condition (FIG. 7A). We found that mechanical stretching can activate the TGFB/SMAD signaling in both human and mouse AT2 cells (FIGS. 7C-7F). When we cultured stretched human or mouse AT2 cells with a TGF^βneutralizing antibody, we found that the increased TGFβ/SMAD signaling in stretched human or mouse AT2 cells can be fully inhibited (FIGS. 7C-7F). These results indicate the autocrine TGF bin human or mouse AT2 cells can activate TGF β /SMAD signaling in these AT2 cells. Together, these results demonstrate that a positive feedback loop of TGF^β/SMAD signaling in stretched AT2 cells further results in increased expression level of autocrine $TGF\beta$. **P<0.01, Student's t test.

[0139] Therefore, the positive feedback loop of TGF β /SMAD signaling in AT2 cells will be an ideal drug target for screening candidate drugs for pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF).

[0140] Example 9. Reducing TGF β signaling in AT2 cells attenuate progression of lung fibrosis

[0141] To further assess the activity of TGFβsignaling in lungs of Control and Cdc42 AT2 null mice at post-PNX day 21, we performed immunostaining experiments with an antibody against p-SMAD2 (FIG. 8A), an indicator of canonical TGFβsignaling activity. Whereas few of the AT2 cells in the Control lungs expressed nuclear p-SMAD2, many AT2 cells in Cdc42 null lungs expressed nuclear p-SMAD2 (FIG. 8A), indicating robust activation of TGFβsignaling in the AT2 cells of Cdc42 AT2 null mice at post-PNX day 21. Many AT2 cells in IPF specimens also expressed nuclear p-SMAD2, demonstrating the activation of TGFβsignaling in AT2 cells of IPF lungs (FIG. 8B).

[0142] It is well-established that the binding of TGFβligand to the TGFBR2 is essential for the activation of TGFβ/SMAD signaling³³. We generated Tgfbr2&Cdc42 AT2 double null mice, in which both Tgfbr2 and Cdc42 genes are deleted in AT2 cells. We performed left lung resection on Cdc42 AT2 null and Tgfbr2&Cdc42 AT2 double null mice and observed these mice for 180 days after PNX (FIG. 8C). Strikingly, 80% of the Tgfbr2&Cdc42 AT2 double null mice were alive by post-PNX day 180, while fewer than 40% of the Cdc42 AT2 null mice were alive by this time (FIG. 8D). These results provide compelling evidence that activated TGFβsignaling in AT2 cells drives the development of lung fibrosis in Cdc42 AT2 null mice. TGF β ligand, Tgfb1, is one of downstream targets of TGF β / SMAD signaling. By qPCR analysis, we found that the expression level of Tgfb1 is significantly increased in Cdc42 null AT2 cells but not in Tgfbr2&Cdc42 double null AT2 cells (FIG. 8E). This indicates that Cdc42 null AT2 cells produce more TGFβligands, due to the increased TGFβ/ SMAD signaling. **P<0.01, Student's t test.

[0143] This example exactly shows that Cdc42 AT2 null mice may be used to find new drug target for IPF like progressive pulmonary fibrosis, and the TGF β signaling in AT2 cells is such an ideal target.

[0144] Results:

[0145] To investigate the long-term effect(s) of impaired alveolar regeneration, we here observed Cdc42 AT2 null and

littermate control (Control) mice for a longer period of time after left lung lobe resection (FIG. 4A). Surprisingly, we found that some Cdc42 AT2 null mice showed significant weight loss and increased respiration rates after post-PNX day 21. Indeed, fully 50% of PNX-treated Cdc42 AT2 null mice reached the predefined health-status criteria for endpoint euthanization by post-PNX day 60 (FIG. 4B), and more than 70% of PNX-treated Cdc42 AT2 null mice

reached their endpoints by post-PNX day 180 (FIG. 4B).

[0146] H&E staining of post-PNX Control and Cdc42 AT2 null mice revealed severe fibrosis in the lungs of Cdc42 AT2 null mice at their endpoints (FIG. 4D compared with FIG. 4C). To determine the point at which Cdc42 AT2 null mice began to develop lung fibrosis following PNX, we analyzed the lungs of Cdc42 AT2 null mice at various time points after PNX using H&E staining (FIG. 4D). The subpleural regions of some Cdc42 AT2 null lungs exhibited signs of tissue thickening by post-PNX day 21 (FIG. 4D). By end-point, the dense fibrosis had progressed to the center of most Cdc42 AT2 null lungs.

[0147] In addition to detecting strong immunohistological signals for Collagen I in these dense fibrotic regions of lungs of Cdc42 AT2 null mice at post-PNX day 21 (FIG. 4E), the area of dense Collagen I in lungs of Cdc42 AT2 null mice gradually increases from post-PNX day 21 to post-PNX day 60 (FIG. 4F). qPCR analysis showed that the Collagen I mRNA expression levels increased gradually from post-PNX day 21 to post-PNX day 60 in lungs of Cdc42 AT2 null mice (FIG. 4G). *P<0.05, ***P<0.001; ****P<0.0001, Student's t test.

[0148] Additionally, there were significant reductions in lung compliance in the PNX-treated Cdc42 AT2 null mice as compared to their PNX-treated Control mice (FIG. **4**H), an intriguing finding given that decreased FVC and decreased lung compliance are known to occur frequently as lungs become fibrotic¹⁹⁻²⁴.

[0149] We also analyzed the lungs of Control and Cdc42 AT2 null mice without PNX treatment and found no significant fibrotic changes before the Cdc42 AT2 null mice reached 10- months of age (FIGS. **5**A-**5**C). By 12 months, fibrosis had obviously begun to develop in the subpleural regions of Cdc42 AT2 null lungs and to progress toward the center of the lung (FIG. **5**C).

[0150] Together, these results indicate that the loss of Cdc42 in AT2 cells leads to progressive lung fibrosis in PNX-treated mice. Moreover, this progressive lung fibrosis phenotype also occurs in no-PNX-treated Cdc42 AT2 null mice starting from around 12 months of age.

[0151] Fibroblastic foci are considered a relevant morphologic marker of progressive pulmonary fibrosis and are recognized as sites where fibrotic responses are initiated and/or perpetuated in progressive pulmonary fibrosis³¹. The fibroblastic foci contain proliferating α - SMA⁺fibroblasts³². So, interested in characterizing the proliferation of the various stromal cell types in fibrotic lungs, we stained the lungs of Cdc42 AT2 null mice with antibodies against α -SMA as well as the cell proliferation marker Ki67 (FIG. **6**A). Some α -SMA⁺fibroblasts started to accumulate next to a cluster of AT2 cells in the relative normal alveolar regions of Cdc42 AT2 null lungs (area 1, FIG. **6**A). And the dense fibrosis region of the lungs is filled with α -SMA⁺fibroblasts (area 2, FIG. **6**A). This analysis revealed that all of the fibrotic lungs contained proliferating α -SMA⁺fibroblasts

[0152] All these results demonstrate that deletion of Cdc42 in AT2 cells leads to IPF like progressive pulmonary fibrosis in mice, and therefore, a mouse model of IPF like progressive lung fibrosis is established and can be used to study human IPF disease.

[0153] 5. Discussion

[0154] As shown above, the loss of Cdc42 in AT2 cells leads to progressive lung fibrosis following lung injury. The progressive development of lung fibrosis that we observed here is apparently similar to the pathological process that occurs in IPF patients, in which fibrosis initially starts at peripheral regions of the lung before slowly proceeding inwards, eventually affecting entire lung lobes.

[0155] All these results demonstrate that deletion of Cdc42 in AT2 cells leads to IPF like progressive pulmonary fibrosis in mice, and therefore, a mouse model of IPF like progressive lung fibrosis is established and can be used to study human IPF disease.

REFERNCES

- **[0156]** 1Wynn, T. A. Cellular and molecular mechanisms of fibrosis. *The Journal of pathology* 214, 199-210, doi: 10.1002/path.2277 (2008).
- [0157] 2Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nature medicine* 18, 1028-1040, doi:10.1038/nm.2807 (2012).
- [0158] 3Mehal, W. Z., Iredale, J. & Friedman, S. L. Scraping fibrosis: expressway to the core of fibrosis. *Nature medicine* 17, 552-553, doi:10.1038/nm0511-552 (2011).
- [0159] 4Barkauskas, C. E. & Noble, P. W. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. *American journal of physiology*. Cell physiology 306, C987-996, doi:10.1152/ ajpce11.00321.2013 (2014).
- [0160] 5Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *Proceedings of the National Academy of Sciences of the United States of America* 108, E1475-1483, doi:10.1073/pnas. 1117988108 (2011).
- [0161] 6Gross, T. J. & Hunninghake, G. W. Idiopathic pulmonary fibrosis. *New England Journal of Medicine* 345, 517-525 (2001).
- **[0162]** 7Vyalov, S. L., Gabbiani, G. & Kapanci, Y. Rat alveolar myofibroblasts acquire alpha- smooth muscle actin expression during bleomycin-induced pulmonary fibrosis. *The American journal of pathology* 143, 1754 (1993).
- [0163] 8King Jr, T. E., Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis. *The Lancet* 378, 1949-1961 (2011).
- [0164] 9Plantier, L. et al. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. *Thorax* 66, 651-657, doi:10. 1136/thx.2010.151555 (2011).
- [0165] 10Steele, M. P. & Schwartz, D. A. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. *Annual review of medicine* 64, 265-276, doi:10.1146/ annurev-med- 042711-142004 (2013).

- **[0166]** 11Camelo, A., Dunmore, R., Sleeman, M. A. & Clarke, D. L. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. *Frontiers in pharmacology* 4, 173, doi:10.3389/fphar.2013.00173 (2014).
- [0167] 12Barkauskas, C. E. et al. Type 2 alveolar cells are stem cells in adult lung. *The Journal of clinical investigation* 123, 3025-3036, doi:10.1172/JCI68782 (2013).
- [0168] 13Desai, T. J., Brownfield, D. G. & Krasnow, M. A. Alveolar progenitor and stem cells in lung development, renewal and cancer. *Nature* 507, 190-194, doi:10.1038/ nature12930 (2014).
- [0169] 14Haies, D. M., Gil, J. & Weibel, E. R. Morphometric study of rat lung cells: I. Numerical and dimensional characteristics of parenchymal cell population. *American Review of Respiratory Disease* 123, 533-541 (1981).
- **[0170]** 15Selman, M. & Pardo, A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross- talk disorder. *Respiratory research* 3, 3 (2001).
- [0171] 16Kropski, J. A., Blackwell, T. S. & Loyd, J. E. The genetic basis of idiopathic pulmonary fibrosis. *European Respiratory Journal* 45, 1717-1727 (2015).
- [0172] 17 Goodwin, A. T. & Jenkins, G. Molecular endotyping of pulmonary fibrosis. *Chest* 149, 228-237 (2016).
- [0173] 18Xu, Y. et al. Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. *JCI insight* 1 (2016).
- [0174] 19Meltzer, E. B. & Noble, P. W. Idiopathic pulmonary fibrosis. *Orphanet journal of rare diseases* 3, 8, doi:10.1186/1750-1172-3-8 (2008).
- [0175] 20Richeldi, L., Collard, H. R. & Jones, M. G. Idiopathic pulmonary fibrosis. *The Lancet* 389, 1941-1952, doi:10.1016/s0140-6736(17)30866-8 (2017).
- [0176] 21TE, J. K. et al. Idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 161, 646-664 (2000).
- [0177] 22Lynch, D. A. et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis

<160> NUMBER OF SEQ ID NOS: 12

<210> SEQ ID NO 1 <211> LENGTH: 21 and prognosis. American journal of respiratory and critical care medicine 172, 488-493 (2005).

- [0178] 23Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *The Lancet* 377, 1760-1769 (2011).
- **[0179]** 24Raghu, G. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American journal of respiratory and critical care medicine* 183, 788-824 (2011).
- [0180] 25Chen, L. et al. Cdc42 deficiency causes Sonic hedgehog-independent holoprosencephaly. *Proceedings* of the National Academy of Sciences 103, 16520-16525 (2006).
- **[0181]** 26Leveen, P. et al. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. *Blood* 100, 560-568 (2002).
- [0182] 27Council, N. R. Guide for the care and use of laboratory animals. (National Academies Press, 2010).
- **[0183]** 28Foltz, C. J. & Ullman-Cullere, M. Guidelines for assessing the health and condition of mice. *Resource* 28 (1999).
- [0184] 29Wang, Y. et al. Pulmonary alveolar type I cell population consists of two distinct subtypes that differ in cell fate. *Proceedings of the National Academy of Sciences*, 201719474 (2018).
- [0185] 30Liu, Z. et al. MAPK-Mediated YAP Activation Controls Mechanical-Tension-Induced
- [0186] Pulmonary Alveolar Regeneration. Cell reports 16,
- 1810-1819, doi:10.1016/j.celrep.2016.07.020 (2016).
- [0187] 31Lynch, D. A. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *The Lancet Respiratory Medicine* 6, 138-153, doi:10.1016/s2213- 2600(17)30433-2 (2018).
- [0188] 32Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. *The New England journal of medicine* 378, 1811-1823, doi:10.1056/NEJMra1705751 (2018).

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic forward primer for Cdc42 <400> SEQUENCE: 1 ctgccaacca tgacaaccta a <210> SEQ ID NO 2 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic reverse primer for Cdc42 <400> SEQUENCE: 2

SEQUENCE LISTING

agacaaaaca acaaggtcca g

<210> SEQ ID NO 3

21

21

10

```
-continued
```

<pre><11> ORGANISM: BUE BUECHISS </pre> <pre><400> SEQUENCE: 3 </pre> <pre>tgttctattt taaagtacag gtaatcalgc atgagaagtc aaaacctta aaactgtcaa</pre>	<211> LENGTH <212> TYPE:	H: 1128 DNA						
<pre>-400> SEQUENCE: 3 igttCtattt taaagtacag gtaatcatgc atgagaagtc aaactatagt caactaagt igttCtattt taaagtacag gtaatcatgc atgagaagtc caactaagt tcaacttaag igcagaacaa tgggaagaag coottcaag tigtoctcig coatctacac atacaccaaa igo iggaggacaca ggtatgtaca gaattcataa citcgtataa tgtatgctat acgaagtat itgaattaaa cataaatat igttCtaat totttatg iggaggagaca itgaagtagg atggictig tggaaaaagt igttCtagt tatactig aagtatgig itgaagga agtocgta iggataaga itgocactig atacacacaa itgaagtag atggictig iggaataaca igttCoogaa iggaggaaca itgaatgigat gatgitcig acactgiagt igcaattit tottottagg acaagaatti itgaaat ataaaataatt igttCoogaa iggaggaat aagaagtig itgitiggig atggictig iggaaaaaa igccoocig agtattitig acigatigta itgitiggig atggictig iggaaaaaa igccoocig agtattitig acigatigi itgitiggig atggictig iggaacaacig agtatgic agtattitig acigatigi itgitigag atggictig iggaagcai gatatatoc ittitattit ittitcito itgitigag atggictig iggaagcig igtataatic itgitigag atggictig iggaagcig agaaggig itaaaaaag iggaggig itgitig iggaaggaa agaaggag igaacaacig ilgigaggig ilgii itgiaaggaagg atacciaaa aaatgaaci ciggocag illis ENCMIN: Sol illis ENCMIN: Sol illis ENCMIN: Mum muculus illis isi ilgiitettat itaaagtacag iggaaggig caacacagga itaacciaaa illii iggaggaacaa iggaaaaga cocciaag itgicitig caacciaag icaactaag illii ilgiitetatt taaagtacag iggaatcaa citgiitetig aaaaccitia aaactgicaa illii ilgiitetati itaagtacag iggaatcaa itgiitetig acigaactaa icaacciaag illii illii ENCMIN: Sol illiii ENCMIN: Mum muculus illiii ENCMIN: Mum muculus illiiii illiiiiiiiiiiiiiiiiiiiiiiiiiii</pre>	<213> ORGANI	SM: Mus mu	Isculus					
tgttetatt taasgtacag gtaatcatge atgagaagte aaaacetta aaacegteag acagtggget getgtgtg geattigetg ecaaceatga caacetaagt teaaettaag geaggacaca iggaataa eccetteag tigteetetig caatetaag taaggaat tegetaaa tageaggig gigtggaacga agteetat etetagaaag taeggaaet tegetagaet agtaeggig taeaeetig aatigetget etggetaggi geeattit tettittag ggttteagt aaggeagaa atgeetet egittaggi geelagaet tegetaggi agaaaagta taggattaaa eataaataat geettaat tetetagg ggaaaaagta 420 tiggattaaa eataaataat geettaat tetetagg acaagaeta 420 tiggattaaa eataaataat geettaat tetetagg acaagaeta 420 tiggattaaa eatagaggi taggaaaa tgeeggaaa taagtgggi 540 gittiggg atggigetig tiggaaaaca tgeteeggaa tgeagaaat taagtgigt 540 sitteeategg aatagtae acatgtaagt ataaaggeti titaetagea aaagatega 600 titeeeategg aatagtae acatgtaag tataeggetig titaeatet 780 egittaagi atagaaggi acaagaet geetgeegga gitteegge 720 cettaaaat aaataaat taateetti tatteettig tgggggegi gittaaaet 780 egittaagi ategaaga aaeagtgae gatattee tittaitti tittitte 900 cetgagaetig ggtteteig tigtaaace gegtagteeg gittaaaet 780 gacaaateag agaceegee geetiggee aggaaggige tataaaaaga giteeggig 1020 giataatga atagtiteg gaaageege aggaaggige tataaaaaga giteegiggi 1020 giataatga agaeeggaaga ataeteaaa aaatgaete eigeeegaag 1128 <210> SEQ ID NO 4 <211> tinnerin: Sei <210> SEQ UD NO 4 <211> tinnerin: Sei <210> SEQ UD NO 4 <211> tinnerin: Sei <210> seggeacaa tiggaaaaga faagatagi eigeeegaaga caaceaga caaceaga taagetea 120 geaagaeaaag geeegaaga ataetetaa aaatgaete eigeeegaaga teaaetig 220 geaaggaeaaa tiggaaaaga eeecteag tigteetet eigeeegaaga taagetaga 120 geaagaeaaag teagitteg geeetig eeeaacaa tagaacaagi 220 geaaggaeaaa gigaatgaa eegittegit titteetetaa aaacettaa aaacegaa ai geeggaacaa gigatgiaa gaateataa ettegtaa tigtaeteaa taegaaagi 220 geaaggaeaaag gigatgiaa gaateataa ettegtaa tigtaeteaa taegaaagi 240 giaceegaat teagitteig geeetiaa ettegtiaa eigaaagte dagaacagt 3300 acegaatat teetittat tittittit tittette teetiaa agaataget tigtagaaget 480 giacegaat teetitteig gaeateegi geeetaaac teggaagategi tigtaaacagt 480 giacegaat teetitteig gaeac	<400> SEQUEN	ICE: 3						
acagtgggct gctgtgtg gcatttget ceaaceatga ceaecatga tacattaag 120 agecaacea ggaagacea ggaagtaca gaatteataa ettegtata tgtatgetat eegaagtat 240 gtegaacga agteetat etetagaag tataggaaet tegetaget agteegegg 300 tacaceetgt aattgeetget etggttaga geetgageet ggetgageet ggtegtagg gaaaaagta 420 tggattgaae agteetat etetagaag tataggaet tegetagg gaaaaagta 420 tggattgaa agteetat etggttagg ggetgageet gtegetagg gaaaaagta 420 tggattgaa agteetat etggttagg ggetgageet gtegetagg gaaaaagta 420 tggattgaa etaaaataat gtettaatt teettetaga acagateta 480 atttgaaat ttaaaagtgg ateeaaaat gteteegaa tgeagacat taagtgetgt 540 gtegtggg agggeetg tggtaaaca tgeteegaa tgeagacat taagtgetgt 540 gtegtaggg atatgtaee acetgtagg geetgeetge gatattette tettetagea aaagtaga 660 teeeaagaata aaataaat tactaeet tataageett ttaetagea aaagtega 660 atgtagggte tgteeatgg aaacaetg geetgeetge agtattette tettette 900 cetgagaetg aggteetgt ggaaacaetg geetgeetga gattetegge etgatgee 960 teaaaeteag agateegeet geetgeetg getgtetgt aceeaaete etggegeg 1020 gtatatgaa taagteege geetgeetge eggatattee tttattett tettette 900 cetgagaetg ggettetetg gaaageege aggaagge etaaaaaga gteetgetg 1020 gtatatga ageeegeaga ataeteaa aaatgaete etgeeegg 1128 	tgttctattt t	aaagtacag	gtaatcatgc	atgagaagtc	aaaaccttta	aaactgtcaa	60	
agoccaacaa tggaaaaaga occottoaag ttgtoototg ocatotaca atacaccaaa 180 goaggacaa ggatgtaca ggattoata ottogtata tgtatgota aogaaggtat 240 gttogaacga agtootatt ototagaaag tataggaact tegotagact agtacgogtg 300 tacacottgt aatigotgot otgagcaag tgocottitt tottittaga ggitticagt 360 catagoagta atgotagta oggatgag gotgagoot gttgotaggg gaaaaagta 420 tggattaaa cataatata gottoot ggittgag gotgagoot gttgotaggg gaaaaagta 420 tggattgaa catagtaca taaaataat gtottaatt totottagg acaagtota 480 attigaaat taaaatgg atacaaac gttoogaa tgocagacat taagtgotgit 540 gttgitiggi atggigotgi tggaaaacg tgococce agtattit gacgacaa taagtgotg 540 cottagag atagtaco aactgtagg atacaaaca tgococce agtattit gacgotgo 720 cottaaaa aaataaatt tactacott tattacttig tgggggggg gtataaact 780 cottaaaa aaataaatt tactacot tattactig tgggggggg gtataaact 780 cottaaaa aaataaat tactoo gottggga aggaaggig ataaaaag gtooggg 960 toaaactog ggtoog gottggga aggaagge tacaaaag 1000 cotgagacig ggttotot gtagcacet gotggaca tggaagga acagtggg 960 toaaactag agaccocce gootggga aggaaggig tataaaag gtooggig 1020 gtatatgaa gatcogoot gootggga aggaaggig tataaaag gtooggig 1020 gtatatgaa gaacagtga gaacgoot toagtgaga aaagatga 128 c210> SEQ ID NO 4 c211> LENNTH: 561 c212> TPY: DNA c210> SEQUENCE: 4 tgttoott ag gtatcata da aatgoot aaaacctag 120 agoccaaca tggaaaaga coottoag tigtoocce caccaaga tacaccaaa 180 gcaggacaa ggatagaag coottoag tigtoocce caccaag taaccacaa 180 gcaggacaa ggatagaag coottoag tigtoocce caccaaga tacaccaaa 180 gcaggacaa tggaaaaga coottoag tigtoocce caccaaga tacaccaaa 180 gcaggacaa tggaaaaga coottoag tigtoocce caccaaga tacaccaaa 180 gcagaccaa tggaaaaga coottoag tigtooce caccacaga tacaccaaa 180 gcagaccaa tggaaaga coottoag tigtooce cacaccaaga tacaccaaa 180 gcagaccaa tggaaaga coottoag tigtootta agaccag tagaacagt 300 accgatat toottitat tittitto ticcotgag coggaacca gagaacagt 300 accgatat toottitat tittitto ticcotgag coggaacca caccaccac afaaccaaa 180 gcagaccaa tggaaaga coottoag tggotaacca cacaccacaa 180 gcagaccaa tggaaaga coottoag tggotaacca cacaccacaa tacaccaaa 180 gcagaccaa tggaaaga coottoag tg	acagtgggct g	gctgtgtgtg	gcatttgctg	ccaaccatga	caacctaagt	tcaacttaag	120	
<pre>graggacaca ggtatgtaca gattcata cttcgtata tgtatgctat acgaagttat 240 gttcgaacga agttcctatt ctctagaag tataggaact tcgctagact agtacgcgtg 300 tacaccttgt aattgctgct ctgagcaagt tgccatttt tcttttaga ggtttcagt 360 catagcagta atgctagtt tggtttggg ggctgagcct gttgctagg gaaaaagta 420 tggatttaaa cataaatcaa taaataatt gtctttaatt tcttcttagg acaagatcta 480 atttgaaat ataaaagtgg atacaaaact gttccgaa tgcagacaat taagtgtgt 540 gttgttggt atggtgctgt tggtaaaac tgtctcctga tatcctaca acaaacaaa 600 ttcccatcgg aatatgtace aactgtaagt ataagggtt ttaattg adgtttg 720 cctttaaaa aaattaaatt tactacctt attacttg tggggtgtg tgtataact 780 cgtatagt atgctaeg agattagg acacgaatta gttctgga ctgggtgtg tgtataact 780 cgtataagt atgctaeg aggtaggt ggtgtdgt tggtaagec gatattce tttatttt tttttcttc 900 cctgagactg ggtttctg tgtagccet gctgtgteg aggaaggtg tataaaag gtctcgtgt 1020 gtatataga tatagttgt gaaagctgt tcagtgag cacacacgca ttatagcaa 1080 gaccaattg agccegaag atacctaa aaatgactaa ctgcccag 1128 </pre>	agcccaacaa t	ggaaaaaga	ccccttcaag	ttgtcctctg	ccatctacac	atacaccaaa	180	
<pre>gttcgaacga agttcctatt ctctagaaag tataggaact tcgctagact agtacgcgtg 300 tacaccttgt aattgctget ctggetagag tgecatttt tetttttaga ggtttcagt 360 catagcagta atgetagte tggtttgag ggetgageet gttgetagg gaaaaagta 420 tggatttaaa cataaateaa taaaataatt gtetttaatt tettettagg acaagateta 480 atttgaaata ttaaaagtgg atacaaaact gttecegaa tgeagacaat taagtgtgtt 540 gttgtgggt atggtgetgt tggtaaaaca tgteteetga tateetacae aacaaacaaa 600 tteceategg aatagtace aactgtaagt ataaaggett tttactage aaagattgta 660 atgtagtgte tgtocattgg aaaacaettg geetgeetg agtattttg aetgtettge 720 cetttaaaa aaattaaat ttactacett tattactttg tggggtgtg gttataact 780 cgtataagt atgetaet ag agttaggt acegaatea ggttetggae etgageet 720 cetttaaaa aaattaaat ttactacett tattactttg tggggtgtg gttataact 780 cgtataatgt atgetatag agttaggt acegaatea ggttetggae etgageet 960 tcaaacteag agateegeet geettggea aggaaggtge tataaaaaga gtetegtgt 1020 gtataaga tatagttgt gaageetgt teggtgag eggaagge gtatataea 1080 gaccaattge ageeegaag atactetaa aaatgaetea etgeeeag</pre>	gcaggacaca g	gtatgtaca	gaattcataa	cttcgtataa	tgtatgctat	acgaagttat	240	
tacacctigt aattgotgot otgagcaagt igocattitt ictittitaga gytticagt 360 catagcagta atgotagtic iggittigag gycigagoot gitgotaggg gaaaaagaa 420 iggattaaaa cataaatcaa taaaataatt gictitaatt ictictiagg acaagatota 460 aittigaaata itaaaagigg atacaaaaci gittocgaa igoagacaa taagigigit 540 gitgitgigg atggigotgi iggaaaaca igotociga tatociaca aacaaacaaa 600 ticocatogg aatagtace aacigtaagt ataaaggott ittactage aaagatigta 660 aigiagigt igotocatigg aaaacactig gootgooige agtattitig acigicitige 720 cottaaaaa aaataaatt itactaccti tattactif iggggigigi gitataacti 780 ogiataatgi atgotataog aagitatgi acogaatoa gittoigga citigigi 900 cotgagactig gyttictoig igagocot gootgooige agtattitt ittittitti 900 cotgagactig gyttictoig igagocot gootgooig agaaggigo citigiga citigigi 960 toaaactoag agatoogooi gootiggoa aggaaggigo tataaaaaga giotogigi 960 toaaactoag agatoogooi gootiggga aggaaggigo tataaaaaga giotogigi 960 toaaactoag agatoogooi gootiggga aggaaggigo tataaaaaga giotogigi 900 gataatgaag tatagtifi gaaagotgot icagigigag cacacacgoa itaatigoaa 1080 gaccaatigo agocgaaga atactoiaa aaatgactoa cigocoag 1128 <210> SEQ ID N0 4 <211> ENNTH: 561 <212> TYPE: DNA <210> SEQUENCE: 4 tgitotatti taaagtacag gitatcago aigagaagto aaaacotta aaacigicaa 60 acagigggot goigigigi gocattago cacaccaga caaccigaa 180 gocgagaccaa tiggaaaga coccitaag tigocotig cocaccaaga cigaagata 240 ggitacegaat icagittoig gactigigi goctigaa cigagatoi cigaagagi a accoacaa tiggaaaaga coccitaag tigocotig cocaccaaga tagaacagtg 300 accegatatat icocitita tittittit titococagaa cigagatagi cigagaagi 240 gocaagaaga ticagittoi gaccitigi goctiaaa tigagacgi cigagaagi cigagacagi 240 gocagagaag ticagittoi gitaging goctaaaa cigagatagi cigagaagi 240 gocagagagi toigaaaaa agagtocgi gitgitatag aagatagit digaaagacgi 440 gitaacgagagi toigaaaaa agagtocgi gitgitatag aagatagit tigagaagi 440 citigotgiti tigaaccaa toigigagig goctaaaa cigagatagi cigagaagi 240 gocagagaagi toigaaaaa agagtocgi gitgitatag aagatagit tigagaagi 440 gitaacgig gocacaa gocacaca goctitaat toigagacogi cigagaagi	gttcgaacga a	gttcctatt	ctctagaaag	tataggaact	tcgctagact	agtacgcgtg	300	
catagongta atgetagtte tggtttgagt ggetgageet gttgetaggg gaaaaagta 420 tggatttaaa cataaateaa taaaataatt gtetttaatt tettettagg acaagateta 480 atttggaata ttaaaagtgg atacaaaaet gtteegaaa tgeagacaat taagtgtgtt 540 gttgttggtg atggtgetgt tggtaaaae tgteteetga tateetaea aacaaaeaaa 600 tteeetaegg aatatgtaee aaetgtaagt ataaaggett tttaetgea aaagattgta 660 atgtagtgte tgteettgg aaaeaettg geetgeetge agtattttg aetgtetteg 720 cetttaaaaa aaattaatt ttaetaeett tattaettig tgggggtgtg gtataaeet 780 egtataagt atgetaeg aagttatgg acegaattee tttattt tttttette 900 cettaagat atgetateg aagttatgg aeeggaaee gatattee tttattt tttttette 900 cetgagaetg ggttetetg tgageeet geettgggea aggaaggtg tataaaag gteegggge 960 teaaaeteag agateegeet geettgggea aggaaggtg tataaaag gteegggg 1020 gtatatgaag tatagttg gaageeg t eaggaaggtg eacaeaegea ttatagea 1080 gaeeaattge ageeegaag ataeetaa aaatgaetea etgeeggg 1128 <210> SEQ ID NO 4 <211> SEQ ID NO 4 <211> SEQ ID NO 4 <211> TEN NNA <212> TEN NNA <212> TEN NNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgtetetatt taaagtag gateegg geatetae etgeggte caacaeega teaaetaeg 120 ageeegaaet ggaaagag ceeettegg caacaetga caaceetta aaaetgtea 180 geaggaeea ggatagtae gaatteeg ttegtette etgegatta egaagetg 300 acegtagaat teegttetg gaeettegg geettegge etgeggtte etgegatee 340 geaggaaegg tgetaaaa agagteeg tegggtgtg getttget etgegaette etgegaette etgegaet geaggaegg tgetaaaa agagteeg getggg getgaaget eagagteeg etgegtte etgegaette geaggaegg tgetaaaa agagteeg getggag etgegaette etgegaette etgegaette etgegaette geaggaeega teegttetg geettagg geeteaaet eagagateeg etgegtte etgegaette etgega	tacaccttgt a	attgctgct	ctgagcaagt	tgccattttt	tctttttaga	ggttttcagt	360	
tygatttaaa cataaatcaa taaaataatt gtotttaatt tottottagg acaagatota 480 atttgaaata ttaaaagtgg atacaaaact gtotoogaaa tgoagacaat taagtgtgtt 540 gttgttggtg atggtgotgt tggtaaaaca tgotootga atacotacaa aacaaacaaa 600 ttocoatogg aatatgtace aactgtaagt ataaaggott tttactagca aaagattgta 660 atgtagtgte tgtcoattgg aaacacttg gootgootge agtattttg actgtottge 720 cotttaaaaa aaattaatt ttactacott tattacttig tggggtgtgt gtataactt 780 cgtataatgt atgotataog aagtatggt accgaattca gtotoggac ctgtgtgtt 840 tgtottaagt atgotataog agtatggt accgaattce tttatttt tttttotte 900 cottgaagactg ggtttottg tgtagcoott gootgootg agaaagge gtataaaaga gtoogggtg 1020 gtatatgaag tatagttag gaacggga aggaaggtge tataaaaga gtooggtgg 1020 gtatatgaag tatagttg gaaagotget tcagtgtgag cacacacgca ttatatgcaa 1080 gaccaattge ageocgaaga atactotaa aaatgactea ctgoccag 1128 <210> SEQ ID NO 4 <211> tENNOTH: 561 <212> TPE NNA <213> ORCANISM: Mus musculus <400> SEQUENCE: 4 tgtottatt taaagtacag gtaatcatge atgagaagte aaaacettta aaactgtcaa 60 acagtggget gotgtgtgg goattegg tgtotcata tgtagcagt atacacatag 120 agcccaacaa tggaaaaga coccttoaag ttgtoctog ccatotacaa tacaccaaa 180 gagggaccaa ggtatgtaca gaattcata cttgotata tgtatgotat acgaagtta 240 ggtaacgaat toogttotg gacctgtgt tttgttotta agtatcaaagt tgaacagtg 300 accgataat tootttatt tttttttt ttottotte ttocotgaag ctgggttte ctgtgtagce 360 cttgotgtte tgtaactace tctgtgagtg goctcaaact cagagatceg cctgoctgg 420 gcaaggaagg tgotataaa agagtoctg gtggtatag agtatagt tgtgaaaget 480 gctaaggt ggtgtaaaa agagtcetg gtggtatag agtatagt tgtgaaaget 480 gctaaggt gg tagtaaca goattaatg cagaccaat tgcagcocga agaatact 540	catagcagta a	atgctagttc	tggtttgagt	ggctgagcct	gttgctaggg	gaaaaaagta	420	
atttgaaata ttaaaagtgg atacaaaact gtttccgaa tgcagacaat taagtgtgtt 540 gttgttggtg atggtgctgt tggtaaaaca tgctcctga tatcctaac aacaaaaaa 600 ttcccatcgg aatatgtacc aactgtaagt ataaaggctt tttactagca aaagattgta 660 atgtagtgtc tgtccattgg aaaacacttg gcctgccgc agtattttg actgtcttgc 720 cotttaaaaa aaattaaatt ttactacott tattactttg tgggggtgt gttataactt 780 cgtataatgt atgctatacg aagtatggt accgaattca gttctggac cttgttgtt 840 tgtcttaagt atacaagtag aacagtgac gatatttc ttttatttt ttttttct 900 cctgagactg ggtttctcg tgtagccctt gctgtctgt aactcact gtgagtggc 960 tcaaactcag agatccgcct gcctgggca aggaaggtgc tataaaaag gtctcgtgg 1020 gtatatgaag tatagttgt gaaagctgct tcagtgtgag cacacacgca ttatagcaa 1080 gaccaattgc agcccgaaga atactctaaa aaatgactca ctgcccag 1128 <210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttctattt taaagtacag gtaatcatgc atgagaagtc caaccacgat tcaacttaag 120 agcccaacaa tggaaaaga cccettcaag ttgtcctg ccatctaca atacccaaa 180 gcaggacca ggtatgtac gaattcata ctgcctag tgtagcta tcagtgtag 240 ggtaccgaat tcagttteg gaccttgtg tttgtgtcta agtaccage tgagatcagt 240 ggtaccgaat tcagttteg gaccttgtg tttgtctta agtaccage 360 cttgetgtte tgtaaccae tctgtgagtg gccttaagt ttgtgtct ctgtgtagcc 360 cttgetgtte tgtaaccae tctgtgagtg gccttagt gtggtatat agtatget tgtgaaagct 480 gccaggaagg tgctataaa agagtccgt gtggtgtg gtggtgtg gcctaact cagagatcg ctegcettg 420 gcaaggaagg tgctataaaa agagtctgt gtggtatag aagtatagtt tgtgaaagct 480 gccaggaagg tgctataaaa agagtccgt gtggtatag aagtatagtt tgtgaaagct 480	tggatttaaa c	cataaatcaa	taaaataatt	gtctttaatt	tcttcttagg	acaagatcta	480	
gtigtiggig atgggetgt tggtaaaca tgeeteega tateetaa aacaacaaa 600 tteeeteega aatagtace aactgtaagt ataaaggett tttaetagea aaagattgta 660 atgtagtgte tgteeattgg aaacaettg geetgeetge agtattttg actgtettge 720 cetttaaaaa aaattaaatt ttaetaeett tattaetttg tgggggggt gttataaett 780 egtataatgt atgetataeg aagtatggt acegaattea gtteetggae ettgtgttt 840 tgeettaagt atgetateeg aagtatggt acegaattee ttttatttt tttttee 900 ceetgagaetg ggtteeteg tgtageeett geegteetg aacteaete ggaggggeg 960 teaaaeteag agateegeet geegteega aegaaggge etataaaaagg gteegtgg 1020 gtatatggaag tatagttigt gaaageetge teagtgtag cacacaegea ttatatgeaa 1080 gaceaattge ageeegaag ataetetaaa aaatgaetea etgeeega 1128 <210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus museulus <400> SEQUENCE: 4 tgtteettt taaagtaeeg gtaateatge atgagaagte caaacegt aaaaetgteaa 60 acagtggget geetgtgtg geattege ceaacetag caacetaag teaaeetaag 120 ageeeaaat ggaaaaga eccetteag tigteeteg ceaacetaag teaaeetaag 120 ageeeaaa tggaaaaga eccetteag tigteeteg ceaacetaag teaaeetaag 120 ageeegaat teagttee gaeettge geetteega etgetaa tgtatgeet aegaagtta 240 ggaaggaeea ggtatgtee gaatteeta ettegtata tgtatgeet aegaagtg 300 acegataat teetttat tittttte tteeetgaag etgegttee citgtagee 360 ettgetgtte tgtaaeetee tetgtagatg geeteage etgggttee etgega 240 geeaaggaagg tgeetataaa agagteeg gtggtgt geetaaae tegaagaege etgegttee 360 ettgetgtte tgtaaeetea tetgtgagt geeteaaet eagaagaege etgegttee etgega 360 ettgetgtte tgtaaeetea tetgtgagt geeteaaet eagaagaeeg etgegttee 480 geeteaggt tgeetataaa agagteeg gtggtatag aagtatagt tggaaaget 480 geeteaggt geetataaaa agagteeg gtggtatag aagtatagt tggaaaget 480	atttgaaata t	taaaagtgg	atacaaaact	gtttccgaaa	tgcagacaat	taagtgtgtt	540	
ttoccatogg aatatgtace aactgtaagt ataaaggett tttactagea aaagattgta 660 atgtagtgte tgtocattgg aaaacacttg geetgeedge agtattttg actgtottge 720 cotttaaaaa aaattaaatt ttactacett tattacttig tgggggtgtg gitataacett 780 ogtataatgt atgetataeg aagtatggt acegaattea gittetggae etigtatt 840 tgtettaagt ategataeg aacagtgae gatatatee tittattit tittetee 900 cotgagaetg ggttteteig tgiageeett getgttetgt aacteactei gigagtggee 960 teaaacteag agateegeet geettgggea aggaaggige tataaaaaga gietegigtg 1020 gtatatgaag tatagttigt gaaagetget teagtgigag cacacaegea titatageaa 1080 gaecaatige ageeegaaga atactetaaa aaatgaetea etigeeega 1128 <210> SEQ ID NO 4 <211> LEENOTH: 561 <212> TYPE DNA <212> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttetattt taaagtaeg giaatteage atgagaagte aaaacetta aaactgie a geegaaeaa tggaaaaaga ceeetteag tigteeeteg ceatectaeg 120 ageeeaata ggaaaaaga ceeetteag tigteeteg ceatectae atacaeaaa 180 geeggaeeaa tggaaaaaga ceeetteag tigteeteg eadetae 240 ggtaeegaat teegttetg gaeettegig tittigtetta agtategaag tagaaeagtg 300 aceegatat teettitat tittitte tteeetgaga etigggitte eitigtagee 360 citgetgite tgtaaeee teetgigg geeteeaaat eagagaege eigiggatee 340 geeggaeegaa teetteg gaeetigg geeteaaat eagagaege eigigstie eitigtagee 360 citgetgite tgtaaeee teetgigg geeteaaat eagagaeee tagaaeagt 300 aceegatatt teettitat tittitte tteeetgaga eigiggitte eigigaaeee 340 geeteegaag tgetataaa agagteeg giggatatag agatatagt tgtgaaaget 480 getteegtgt gigtaeaaaa agagteeg gigtgatatg aagatatgit tgtgaaaget 480 getteegtgt gedeacaee geettatatg eagaeeeat tgeegeeega agaataette 540	gttgttggtg a	atggtgctgt	tggtaaaaca	tgtctcctga	tatcctacac	aacaaacaaa	600	
atgtagtgt tytceattgg aaaacaettg geetgeetge agtattttg actgtettge 720 cotttaaaaa aaattaaatt ttactaectt tattaetttg tggggtgtg gttataactt 780 cgtataatgt atgetataeg aagttatgg acegaattea gtttetggae ettgtgttt 840 tgtettaagt ateaaagtag aacagtgaee gatatattee ttttatttt tttttette 900 cetgagaetg ggttetetg tgtageeett getgttetgt aacteaetet gtgagtggee 960 teaaacteag agateegeet geettggea aggaaggtge tataaaaaga gteeggtgg 1020 gtatatgaag tatagttgt gaaagetget teagtgtgag cacacaegea ttatatgeaa 1080 gaceaattge ageeegaaga ataetetaaa aaatgaetea etgeeeag 1128 <210> SEQ ID NO 4 <211> LENGTM: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttetattt taaagtacag gtateatge aggaaggt geaaceatge teaactaag 120 ageeegaaea ggtatgtee gaatteetge tgtgtetgt agtatee ataeaaga taegetga geaggaeaea ggtatgtee gaatteetg tgtgtettg ecaaceagg tagaaceatg 240 ggtaeegaat teegttteg gaactegtg tttgtetta agtateaag tagaacagtg 300 accgatatat teetttatt ttttttte tteeetgag etgggttet etgggaace 240 ggaaggaagg tgeetaaaa agagteeg geeteeaact eagagaaceg etgggttet etgtgaace teggaaeaag teetgtgg geettee teggagaege etgggttet etgtgaaeagt 480 getteeggt gtgtagt gtaetaaa agagteeg geeteaact eagagaaegt 480 getteeggt gtgtataa agagteeg tgtggtatatg aagtatagtt tgtgaagee 480 getteeggt gageeeaea geattatag caagateeg tgegetatg teggaaeaegt 540	ttcccatcgg a	atatgtacc	aactgtaagt	ataaaggctt	tttactagca	aaagattgta	660	
cctttaaaaa aaattaaatt ttactacctt tattactttg tggggtgtg gttataactt 780 cgtataatgt atgctatacg aagttatggt accgaattca gtttctggac cttgttgttt 840 tgtcttaagt atcaaagtag aacagtgace gatatattee ttttatttt tttttette 900 cctgagactg ggttetetg tgtagecett getgtetgt aacteacted gtgagtggee 960 teaaacteag agateegeet geettgggea aggaaggtge tataaaaaga gteegtgtg 1020 gtatatgaag tatagttgt gaaagetget teagtgtgag cacacaegea ttatatgeaa 1080 gaccaattge ageeegaaga atactetaaa aaatgactea etgeceag 1128 <210> SEQ ID NO 4 <211> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttetattt taaagtacag gtaateatge atgagaagte aaaacettaa aaactgteaa 60 accagtggget gedgtgtg geatttgetg ceaaceatga caacetaagt teaaetaag 120 ageeegaaaaaga cecetteaag ttgteetetg ecatetaae 180 geaggaacaa ggtatgtaca gaatteataa ettegtataa tgtatgetat acgaagttat 240 ggtacegaat teagtttetg gacettgttg tttgtetta agtateaag tagaacagtg 300 accgatatat teettttatt tttttttte tteeetgaga etgggtttet etgtgtagee 360 cttgetgtte tgtaaceae tetgtgagt geeteaaet eaggaateet 240 ggtaacggaag tgetataaa agagteeg gtggtatatg aagtatagt tgtgaaaget 480 getteagtgt gageeeaee geattatag caggaeeaa tgeageaget 480 getteagtgt gageeeaee geattatag cagaaceat tegageaeed 540	atgtagtgtc t	gtccattgg	aaaacacttg	gcctgcctgc	agtatttttg	actgtcttgc	720	
cgtatatgt atgctatacg aagttatggt accgaattca gtttctggac cttgttgtt 840 tgtottaagt atcaaagtag aacagtgacc gatatatco ttttatttt tttttotto 900 cotgagactg ggtttototg tgtagocott gotgttotgt aactoactot gtgagtggoc 960 tcaaactcag agatcogoot goottgggca aggaaggtge tataaaaaga gtotogtgtg 1020 gtatatgaag tatagttgt gaaagotgot toagtgtgag cacacacgoa ttatatgoaa 1080 gaccaattge ageocgaaga atactotaaa aaatgactea etgeocag 1128 <210> SEQ ID NO 4 <211> ENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttotattt taaagtacag gtaatcatge atgagaagte aaaacottta aaactgtcaa 60 accagtggget gotgtgtgt goatttgetg ccaaccatga caacctaagt tcaactaag 120 ageocaacaa tggaaaaaga cocottcaag ttgtoctotg ccatotacca ataccacaa 180 gcaggaccaac ggtatgtaca gaattcata ettegtataa tgtatgota acgaagttat 240 ggtaccgaat tcagtttetg gacettgtg ttttgtotta agtatcaag tagaacagtg 300 accgatatat tcetttatt ttttttte ttocotgaga ctgggtttet etgtgtagoe 360 cttgetgtte tgtaactea ctegtgagtg gcotcaaact caggagateg ctggetgtg 420 gcaaggaagg tgetataaa agagteteg tgtgtatatg agtatagtt tgtgaaaget 480 gctcagtgt gagcacaca gcattatg caagaccaat tgcagcega agaatactt 540	cctttaaaaa a	aattaaatt	ttactacctt	tattactttg	tggggtgtgt	gttataactt	780	
tgtcttaagt atcaaagtag aacagtgace gatatattee ttttatttt tttttette 900 octgagaetg ggtttetetg tgtageeett getgttetgt aacteactet gtgagtggee 960 teaaaeteag agateegeet geettgggea aggaaggtge tataaaaaga gtetegtggg 1020 gtatatgaag tatagttgt gaaagetget teagtgtgag cacacaegea ttatatgeaa 1080 gaceaattge ageeegaaga atactetaaa aaatgaetea etgeeeag 1128 <210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus museulus <400> SEQUENCE: 4 tgttetattt taaagtacag gtaateatge atgagaagte aaaaecetta aaaetgteaa 60 accagtggget getgtgtg geattgetg ceaaecatga ceaectaagt teaaettaag 120 ageecaaeaa tggaaaaaga eccetteaag ttgteeteg ceateaeag tagaaegtat 240 ggtacegaat teagttetg gacettgetg tttgteeta agtateaeg aggaaegtg 300 accgatatat teetttatt ttttttte tteeetgaga etgggtttet etgtgaaeeg 300 accgatatat teetttatt tttttttte tteeetgaga etgggttet etgtgaaeeg 420 getaaggaagg tgetataaa agagteeg gegtatatg aagatagtt tgtgaaaget 480 getteegtgt gageacaee geattatag caagaecaat tgeageeeg 480	cgtataatgt a	atgctatacg	aagttatggt	accgaattca	gtttctggac	cttgttgttt	840	
cctgagactg ggtttetetg tgtageeett getgttetgt aacteaetet gtgagtggee 960 teaaaeteag agateegeet geettgggea aggaaggtge tataaaaaga gtetegtgg 1020 gtatatgaag tatagtttgt gaaagetget teagtgtgag cacaeaegea ttatatgeaa 1080 gaceaattge ageeegaaga ataetetaaa aaatgaetea etgeeeag 1128 <210> SEQ ID NO 4 <211> SEQ ID NO 4 <211> ENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus museulus <400> SEQUENCE: 4 tgttetattt taaagtaeag gtaateatge atgagaagte aaaaeettta aaaetgteaa 60 acagtgggget getgtgtgt geeattgetg ceaaeeatga caaeeetaag teaaettaag 120 ageeeaaeaa tggaaaaaga eeeetteaag ttgteeteg eeaaeet ateeaaeaa 180 geaggacaea ggtatgtee gaatteata ettegtataa tgtatgetat aegaagtta 240 ggtaeegaat teagttetg gaeettgetg ttttgtetta agtateaag tagaacagtg 300 accgatatat teettttatt tttttttte tteeetgaga etgggttet etgtgtagee 360 ettgetgtte tgtaaeteae teggagg geeteaaaet eagagateeg etggetteg 420 geaaggaagg tgetataaa agagteteg gtggtatatg aagtatagtt tgtgaaaget 480 getteagtgt gageacaeae geattatatg caagaceaat tgeageeega agaataette 540	tgtcttaagt a	atcaaagtag	aacagtgacc	gatatattcc	ttttatttt	ttttttcttc	900	
tcaaactcag agatcegeet geettgggea aggaaggtge tataaaaaga gtetegtgtg 1020 gtatatgaag tatagtttgt gaaagetget teagtgtgag cacacaegea ttatatgeaa 1080 gaccaattge ageeegaaga ataetetaaa aaatgaetea etgeeeag 1128 <210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttetattt taaagtaeag gtaateatge atgagaagte aaaacettta aaaetgteaa 60 acagtggget geetgtgtgt geatttgetg ceaceacatga caacetaagt teaaettaag 120 ageeegaacaa tggaaaaaga eccetteaag ttgteetetg ecatetaea ataeaeeaaa 180 geaggaeaea ggtatgtaea gaatteataa ettegtataa tgtatgetat aegaagttat 240 ggtaeegaat teagttetg gaeettgetg tttgtetta agtateaaga tagaacagtg 300 accgattat teetttatt tttttttte tteeetgaga etgggtttet etgtgaaee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgggtttet etgtgaagee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgegttte etgtgaagee 360 ettgetgtte tgtaaeteae tegtgggtg geeteaaaet eagagateeg etgegttee etgtgaaeee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgegttee etgegaagee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgegttee etgegaaeee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgegettee etgegaaeee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgegettee etgegaaeee 360 ettgetgtte tgtaaeteae tegtgagtg geeteaaaet eagagateeg etgeettaga 480 geeteagtgt gageaeeae geattatatg eagaeeaat tgeageeega agaataeete 540	cctgagactg g	gtttctctg	tgtagccctt	gctgttctgt	aactcactct	gtgagtggcc	960	
gtatatgaag tatagtttgt gaaagctgct teagtgtgag eacaeaegea ttatatgeaa 1080 gaceaattge ageeegaaga ataetetaaa aaatgaetea etgeeeag <211> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttetattt taaagtacag gtaateatge atgagaagte aaaaeettta aaaetgteaa 60 acagtgggget getgtgtgtg geatttgetg eeaaeeatga eaaeeetaagt teaaettaag 120 ageeeaaeaa tggaaaaaga eeeetteag ttgteetetg eeateetaae ataeaeeaaa 180 geaggaeeae ggtatgteet gaeettgetg tttgtetta agtateaag tagaaeagtg 300 accgatatat teettttatt ttttttte tteeetgaga etgggttet etgtgtagee 360 ettgetgtte tgtaaeteae tetgtgagtg geeteaaeet eagagateeg eetgegtetg 420 geaaggaagg tgeetaaaaa agagtetegt gtggtatatg aagtatagtt tgtgaaaget 480 geeteagtgt gageaeeee geetatatg eagageeeat tegegeeega agaataetet 540	tcaaactcag a	agatccgcct	gccttgggca	aggaaggtgc	tataaaaaga	gtctcgtgtg	1020	
gaccaattge ageeegaaga ataeteetaaa aaatgactea etgeeegag <210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttetatt taaagtacag gtaateatge atgagaagte aaaacettta aaacetgteaa 60 acagtgggget getgtgtgtg geatttgetg ecaaceatga caacetaagt teaaettaag 120 ageeegaacaa tggaaaaaga eceetteaag ttgteeteetg ecatetaeca ataeaeegaa 180 geaggacaca ggtatgtaca gaatteataa ettegtataa tgtatgetat acgaagttat 240 ggtacegaat teagttteetg gacettgetg ttttgteetta agtateaaag tagaaeagtg 300 accegatatat teettttatt ttttttte tteeetgaga etgggtttee etgetgtagee 360 ettgetgete tgtaaeteae teetgtgagtg geeteaaeet eagagateeg eeegeettg 420 geaaggaagg tgetataaaa agagteeeg egggtatatg aagtatagtt tgtgaaageet 480 getteagetg gageacaaca geattatatg caagaceaat tgeageeega agaataeett 540	gtatatgaag t	atagtttgt	gaaagctgct	tcagtgtgag	cacacacgca	ttatatgcaa	1080	
<pre><210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus <400> SEQUENCE: 4 tgttctattt taaagtacag gtaatcatgc atgagaagtc aaaaccttta aaactgtcaa 60 acagtgggct gctgtgtgtg gcatttgctg ccaaccatga caacctaagt tcaacttaag 120 agcccaacaa tggaaaaaga ccccttcaag ttgtcctctg ccatctacac atacaccaaa 180 gcaggacaca ggtatgtaca gaattcataa cttcgtataa tgtatgctat acgaagttat 240 ggtaccgaat tcagtttctg gaccttgttg ttttgtctta agtatcaaag tagaacagtg 300 accgatatat tccttttatt tttttttt ttc ttccctgaga ctgggtttct ctgtgtagcc 360 cttgctgttc tgtaactcac tctgtgagtg gcctcaaact cagagatcg cctgccttgg 420 gcaaggaagg tgctataaaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcaccaca gcattatatg caagaccaat tgcagcccga agaatactct 540</pre>	gaccaattgc a	igcccgaaga	atactctaaa	aaatgactca	ctgcccag		1128	
<pre><400> SEQUENCE: 4 tgttctattt taaagtacag gtaatcatgc atgagaagtc aaaaccttta aaactgtcaa 60 acagtgggct gctgtgtgg gcatttgctg ccaaccatga caacctaagt tcaacttaag 120 agcccaacaa tggaaaaaga ccccttcaag ttgtcctctg ccatctacac atacaccaaa 180 gcaggacaca ggtatgtaca gaattcataa cttcgtataa tgtatgctat acgaagttat 240 ggtaccgaat tcagttctg gaccttgttg ttttgtctta agtatcaaag tagaacagtg 300 accgatatat tccttttatt ttttttttc ttccctgaga ctgggtttct ctgtgtagcc 360 cttgctgttc tgtaactcac tctgtgagtg gcctcaaact cagagatccg cctgccttgg 420 gcaaggaagg tgctataaaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcacacac gcattatatg caagaccaat tgcagcccga agaatactct 540</pre>	<210> SEQ ID NO 4 <211> LENGTH: 561 <212> TYPE: DNA <213> ORGANISM: Mus musculus							
tgttctattt taaagtacag gtaatcatge atgagaagte aaaacettta aaactgteaa 60 acagtggget getgtgtg geattgetg ecaaceatga eaaeetaag teaaettaag 120 ageeegaacaa tggaaaaaga eeeetteag ttgteetetg eeatetaaa ataeaeeaaa 180 geaggaeeaa ggatgtaea gaatteataa ettegtataa tgtatgetat aegaagttat 240 ggtaeegaat teagtteeg gaeettgttg tttgtetta agtateaaag tagaaeagtg 300 aeegatatat teetttatt ttttttte tteeetgaga eegggttee etgegagee 360 ettgeetgtte tgtaaeteae teegtgagtg geeteaaaet eagaagteeg eetgeettgg 420 geaaggaagg tgetataaaa agagtetegt gtggtatatg aagtatagtt tgtgaaagee 480 getteagtgt gageeeaee geattatatg eaagaeeaat tgeageeega agaataetee 540	<400> SEQUEN	ICE: 4						
acagtgggct gctgtgtgt gcatttgctg ccaaccatga caacctaagt tcaacttaag 120 agcccaacaa tggaaaaaga ccccttcaag ttgtcctctg ccatctacac atacaccaaa 180 gcaggacaca ggtatgtaca gaattcataa cttcgtataa tgtatgctat acgaagttat 240 ggtaccgaat tcagtttctg gaccttgttg ttttgtctta agtatcaaag tagaacagtg 300 accgatatat tccttttatt ttttttttc ttccctgaga ctgggtttct ctgtgtagcc 360 cttgctgttc tgtaactcac tctgtgagtg gcctcaaact cagagatccg cctgccttgg 420 gcaaggaagg tgctataaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcacaca gcattatatg caagaccaat tgcagcccga agaatactct 540	tgttctattt t	aaagtacag	gtaatcatgc	atgagaagtc	aaaaccttta	aaactgtcaa	60	
agcccaacaa tggaaaaaga ccccttcaag ttgtcctctg ccatctacac atacaccaaa 180 gcaggacaca ggtatgtaca gaattcataa cttcgtataa tgtatgctat acgaagttat 240 ggtaccgaat tcagttctg gaccttgttg ttttgtctta agtatcaaag tagaacagtg 300 accgatatat tccttttatt tttttttt ttcctcctgaga ctgggtttct ctgtgtagcc 360 cttgctgttc tgtaactcac tctgtgagtg gcctcaaact cagagatccg cctgccttgg 420 gcaaggaagg tgctataaaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcacaca gcattatatg caagaccaat tgcagcccga agaatactct 540	acagtgggct g	gctgtgtgtg	gcatttgctg	ccaaccatga	caacctaagt	tcaacttaag	120	
gcaggacaca ggtatgtaca gaattcataa cttcgtataa tgtatgctat acgaagttat 240 ggtaccgaat tcagttctg gaccttgttg ttttgtctta agtatcaaag tagaacagtg 300 accgatatat tccttttatt ttttttttc ttccctgaga ctgggtttct ctgtgtagcc 360 cttgctgttc tgtaactcac tctgtgagtg gcctcaaact cagagatccg cctgccttgg 420 gcaaggaagg tgctataaaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcacacac gcattatatg caagaccaat tgcagcccga agaatactct 540	agcccaacaa t	ggaaaaaga	ccccttcaag	ttgtcctctg	ccatctacac	atacaccaaa	180	
ggtaccgaat teagttetg gaeettgttg tittgtetta agtateaaag tagaacagtg 300 acegatatat teettitatt tittitte titeeetgaga etgggtitet etgtgagee 360 ettgetgtte tgtaacteae tetgtgagtg geeteaaact eagagateeg eetgeettgg 420 geaaggaagg tgetataaaa agagtetegt gtggtatatg aagtatagtt tgtgaaaget 480 getteagtgt gageacacae geattatatg eaagaecaat tgeageeega agaataetee 540	gcaggacaca g	gtatgtaca	gaattcataa	cttcgtataa	tgtatgctat	acgaagttat	240	
accgatatat teetttatt ttttttte tteeetgaga etgggtttet etgtgtagee 360 ettgetgtte tgtaacteae tetgtgagtg geeteaaaet eagagateeg eetgeettgg 420 geaaggaagg tgetataaaa agagtetegt gtggtatatg aagtatagtt tgtgaaaget 480 getteagtgt gageacaeae geattatatg eaagaecaat tgeageeega agaataetet 540	ggtaccgaat t	cagtttctg	gaccttgttg	ttttgtctta	agtatcaaag	tagaacagtg	300	
cttgctgttc tgtaactcac tctgtgagtg gcctcaaact cagagatccg cctgccttgg 420 gcaaggaagg tgctataaaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcacacac gcattatatg caagaccaat tgcagcccga agaatactct 540	accgatatat t	ccttttatt	tttttttc	ttccctgaga	ctgggtttct	ctgtgtagcc	360	
gcaaggaagg tgctataaaa agagtctcgt gtggtatatg aagtatagtt tgtgaaagct 480 gcttcagtgt gagcacacac gcattatatg caagaccaat tgcagcccga agaatactct 540	cttgctgttc t	gtaactcac	tctgtgagtg	gcctcaaact	cagagatccg	cctgccttgg	420	
getteagtgt gageacaeae geattatatg eaagaecaat tgeageeega agaataetet 540	gcaaggaagg t	gctataaaa	agagtctcgt	gtggtatatg	aagtatagtt	tgtgaaagct	480	
	gcttcagtgt g	Jagcacacac	gcattatatg	caagaccaat	tgcagcccga	agaatactct	540	
aaaaaatgac tcactgccca g 561	aaaaaatgac t	cactgecca	g		5		561	

<210> SEQ ID NO 5 <211> LENGTH: 23 <212> TYPE: DNA 11

-continued

<213> ORGANISM: Artificial Sequence <220> FEATURE <223> OTHER INFORMATION: Synthetic forward primer for Gapdh <400> SEQUENCE: 5 aaggtcggtg tgaacggatt tgg 23 <210> SEQ ID NO 6 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic reverse primer for Gapdh <400> SEQUENCE: 6 cgttgaattt gccgtgagtg gag 23 <210> SEQ ID NO 7 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic forward primer for Colla1 <400> SEQUENCE: 7 22 cctcagggta ttgctggaca ac <210> SEQ ID NO 8 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic reverse primer for Colla1 <400> SEQUENCE: 8 cagaaggacc ttgtttgcca gg 2.2 <210> SEQ ID NO 9 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic forward primer Human Tgfb1 <400> SEQUENCE: 9 22 tacctgaacc cgtgttgctc tc <210> SEQ ID NO 10 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic reverse primer for Human Tgfb1 <400> SEQUENCE: 10 22 gttgctgagg tatcgccagg aa <210> SEQ ID NO 11 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic forward primer for Mouse Tgfb1

<400> SEQUENCE: 11	
tgatacgcct gagtggctgt ct	22
<210> SEQ ID NO 12 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic reverse primer for Mouse Tgfb1	
<400> SEQUENCE: 12	
cacaagagca gtgagcgctg aa	22

1. A method for constructing an animal model of pulmonary fibrosis, comprising a step of increasing mechanical tension on alveolar epithelium of an animal.

2. The method of claim **1**, wherein before the step of increasing the mechanical tension on the alveolar epithelium, the animal undergoes a pneumonectomy (PNX).

3. The method of claim **1**, wherein the step of increasing the mechanical tension on the alveolar epithelium includes a step of increasing mechanical tension on alveolar type II (AT2) cells.

4. The method of claim **3** wherein the step of increasing the mechanical tension on alveolar type II (AT2) cells involves a step of deactivating Cdc42 in AT2cells.

5. The method of claim **4**, wherein deactivating Cdc42 in AT2 cells involves deleting, disrupting, inserting, knocking-out or inactivating Cdc42 genes in AT2 cells.

6. The method of claim **1**, comprising a step of knockingout Cdc42 gene in AT2 cells in a PNX-treated animal.

7. The method of claim 6, wherein the knockout of Cdc42 gene in AT2cells leads to progressive lung fibrosis in the PNX-treated animal.

8. The method of claim **7**, wherein the progressive lung fibrosis phenotype occurs in non-PNX-treated Cdc42 AT2 null animals in middle age and old age.

9. The method of claim **6**, wherein in the lungs of Cdc42 AT2 null animals, fibroblastic foci are developed.

10. The method of claim **1**, wherein the animal is mouse, rabbit, rat, canine, pig, horse, cow, sheep, monkey or chimpanzee.

11. An animal model of pulmonary fibrosis constructed through increasing mechanical tension on alveolar epithelium of an animal.

12. The animal model of claim **11**, wherein the animal model is constructed through increasing mechanical tension on AT2cells of the animal, and/or the mechanical tension on the alveolar epithelium of the animal is increased.

13. (canceled)

14. The animal model of claim 12, wherein Cdc42 gene in AT2 cells is deactivated, deleted, disrupted, inserted, knocked-out or inactivated.

15-16. (canceled)

17. The animal model of claim **11**, wherein the animal model shows progressive lung fibrosis phenotype after undergoing PNX and/or develops fibrotic changes after the pneumonectomy (PNX) treatment.

18. The animal model of claim **11**, wherein the animal model without undergoing PNX shows progressive lung fibrosis phenotype in middle age and old age.

19. The animal model of claim **11**, wherein the fibroblastic foci are developed.

20.(canceled)

21. The animal model of claim **14**, wherein the animal model shows genotype of Cdc42 AT2 null.

22. The animal model of claim **14**, wherein the animal model is Cdc42 AT2 null mouse.

23. The animal model of claim **11**, wherein the animal is mouse, rabbit, rat, canine, pig, horse, cow, sheep, monkey, or chimpanzee.

24-32. (canceled)

33. A method for screening candidate drugs or a drug target for treating pulmonary fibrosis of animals and human beings, comprising using an animal model of pulmonary fibrosis constructed through increasing mechanical tension on alveolar epithelium of an animal, or using an AT2cell of lung in which the mechanical tension on the alveolar epithelium is increased.

34. (canceled)

35. The method of claim **33**, wherein one kind of drug target, involving a positive feedback loop of TGF β /SMAD signaling in human or mouse AT2cells is searched out.

36. The method of claim **35**, wherein the autocrine TGF β in human or mouse AT2 cells activates TGF β /SMAD signaling in AT2 cells.

37. The method of claim **35**, wherein the expression level of autocrine TGF β in both human and mouse AT2 cells is significantly increased by mechanical stretching.

38. The method of claim **37**, wherein the positive feedback loop of TGF β /SMAD signaling in stretched human and mouse AT2 cells further results in the increased expression level of autocrine TGF β .

39. (canceled)

40. The method of claim **33**, wherein the animal is mouse, rabbit, rat, canine, pig, horse, cow, sheep, monkey or chimpanzee.

41. A method for evaluation of the therapeutic effects or prognosis evaluation of pulmonary fibrosis using the animal model of claim **11**.

42. (canceled)

43. A method for detecting the animal model of claim **11** using a pair of primers designed on the basis of the sequences shown by SEQ ID NO:4.

44. The method of claim 43, wherein the primers for detecting the said animal model are shown as followed:

Forward: CTGCCAACCATGACAACCTAA; Reverse: (SEQ ID NO: 1) AGACAAAACAACAAGGTCCAG.

45. The method of claim **1**, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

46. The animal model of claim **11**, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

47. The method of claim 33, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

48. The method of claim **6**, wherein the step of knockingout Cdc42 gene in AT2 cells in the PNX-treated animal comprises knocking out Cdc42 specifically in lung AT2 cells by using a Spc-CreER allele.

* * * * *